Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 1of 116Clinical Study Protocol 
IMP AZD7442
Study Code D8850C00003
Version 6.[ADDRESS_904695] of T wo Monoclonal Antibodies (AZD8895 and 
AZD1061), for Post -exposure Prophylaxis of COVID -19
Sponsor  Name: [CONTACT_245011]: 151, 85 Södertälje, Sweden
Regulatory Agency Identifier  Number(s): IND number: [ADDRESS_904696] Number: [ADDRESS_904697] procedures. The Clinical Study Protocol is publicly regis tered, and the resul ts are 
disclosed and/or published according to the [COMPANY_008] Global Policy on Bioethics and in 
compliance wi th prevailing laws and regulat ions.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 2of 116Protocol Number : D8850C00003
Amendment Number : Amendment 5 
IMP : AZD7442 
Study Phase :Phase III
Short Title : Phase III Doubl e-blind, Placebo -controlled Study  of AZD7442 for Post -exposure 
Prophylaxis o f COVID -19 in Adults
Acronym: STORM CHASER: COVID -[ADDRESS_904698] Information will be pr ovided separately
International Co-ordinating Investigator : [CONTACT_670117] J Levin
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 3of 116PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE
DOCUMENT HISTORY
Document Date
Version 6.0 [Amendment 5] 12March 2021
Version 5.0 [Amendment 4] 21 December 2020
Version 4.0 [Amendment 3] 16 December 2020
Version 3.0 [Amendment 2] 13 November 2020
Version 2.0 [Amendment 1] 26 October 2020
Original Protocol 07 October 2020
Version 6.0, 1 2March 2021
Key amendment and rationale for change:
Highly efficacious vaccines against SARS -CoV-[ADDRESS_904699] been adjusted accordingly . 
Synopsis, Sections 1.2 (Schema), 3 (Objectives and Endpoints), 4.1 ( Overall Design), 
6.1.1 (Investigational Medicinal Pr oducts), 9.4 (Statistical Analysis), [IP_ADDRESS] (Primary 
Endpoint(s)), Table 1 (Sche dule of Activities: T reatment and Follow -up Period –Main 
Study): To provi de safet y and PK assessments after [ADDRESS_904700] this addit ional time point.
Synopsis, Sections 4.1 (Overall Design) and 6.3.1 (Randomization): Caps for Cohorts 1 
and 2, not to exceed 80% of the total participants rando mized, have been removed. The 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 4of 116recrui tment of parti cipants fro m long term  care f acilities is no l onger feasible wit h the 
increased availabilit y of vaccinat ions to this population.
Synopsis, Sections 4.2.1 (Rationale for  Study Endpoints): Recent attack rates for 
COVID -[ADDRESS_904701] substant ially decreased and may  continue to decrease wi th availabili ty of 
vaccines to a broader populat ion. To accommodate the changing attack rate the primary 
efficacy analysis will be conducted 30 day s after the 25thevent has been confirmed. 
Synopsis, Sections 9.1 (Statistical Hypotheses), 9.2 (Sample Size Dete rmination), 9.4 
(Statistical Analyses), [IP_ADDRESS] (Primary Endpoint), 9.4.5 (Methods for  Multiplicity 
Contr ol), 9.5 (Interim Analyses), 9.6 (Data Safety Monitoring Board), and Appendix 
A5 (Committees Structur e):The primary endpo int assumpt ions have been rev ised to 
reflect changing expectations regarding the attack rate. The primary analysis will be 
conducted [ADDRESS_904702] been removed. 
Table 1 (Schedule of Activities: T reatment and Follow -up Period –Main Study): 
During screening the eCRF is already capturing participant ECOG grade and therefore, for 
consistency , Perf ormance Status has been added to Medical History . ECOG performance 
status grades have been included in Appendix G for reference.
Section 2.2.2 (Summary of Nonclinical Pharmacokinetics and Drug Metabolism):
Safety margins updated with emerging data from Phase I study . Results from cyno molgus 
monkey GLP toxicology study updated with week 8 data.
Section 6.5 (Concomitant Therapy) and T able 6 (Permitted, Restricted, and Pr ohibited 
Medications): Text updated to specify that any COVID -[ADDRESS_904703] 30 days prior to V isit 1 and there are no 
anticipated changes during the treatment period. The s tipulat ion that commercial bio logics, 
prednisone, or immunosuppressive medicat ions should not be administered on the same day 
of IMP has been removed. Clarificat ion that bl ood/pl asma donati on restri ction is for one 
year not 5 half -lives. 
Section 8.1.1 (Mo nitoring COVID -19 Symptoms) : To ensure participants with qualifying 
COVID -[ADDRESS_904704] be enrolled on Illness V isits immediately but no later than 3 days o f those symptoms 
being identified.
Clinical Study P rotocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 5of 116Previous amendments are summarized in Appendix I.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 6of 116TABLE OF CONTENTS
TITLE PAGE ................................ ................................ ................................ ........................ [ADDRESS_904705] ivities................................ ................................ ....................... 15
2 INTRODUCTION ................................ ................................ ............................ 22
2.1 Study  Rati onale ................................ ................................ ................................ 22
2.2 Background ................................ ................................ ................................ ......22
2.2.1 Summary  of Nonclinical Pharmaco logy................................ ............................ 23
2.2.2 Summary  of Nonclinical Pharmacokinet ics and Drug Metabolism .................... 24
2.2.3 Summary  of Toxico logy................................ ................................ ................... 25
2.3 Benefit/Risk Assessment ................................ ................................ ................... 26
2.3.1 Risk Assessment ................................ ................................ ............................... 26
2.3.2 Benefit Assessment ................................ ................................ ........................... 27
2.3.3 Overall Benefit: Risk Conclusio n................................ ................................ ......[ADDRESS_904706] ions................................ ................................ ........................ 36
[IP_ADDRESS] Women of Non Childbearing Potential ................................ .............................. 36
[IP_ADDRESS] Women of Childbearing Potential ................................ ................................ .....36
[IP_ADDRESS] Male Parti cipants ................................ ................................ .............................. 37
5.4 Screen Failures ................................ ................................ ................................ .37
6 STUDY INTERV ENTION ................................ ................................ ............... 38
6.1 IMP(s) Administered ................................ ................................ ........................ 38
6.1.1 IMP ................................ ................................ ................................ .................. 38
6.2 Preparati on/Handling /Storage/Accountabilit y................................ ................... 39
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 7of 1166.2.1 Dose Preparation and Administration Instructions ................................ ............. 39
[IP_ADDRESS] Invest igational Product Inspect ion................................ ................................ ....40
[IP_ADDRESS] Dose Cal culat ion................................ ................................ ............................... 40
[IP_ADDRESS] Dose Preparation Steps ................................ ................................ ..................... 40
6.3 Measures to Minimize Bias: Rando mizat ion and Blinding ................................ 41
6.3.1 Randomization ................................ ................................ ................................ ..41
6.3.2 Blinding ................................ ................................ ................................ ............ 42
6.3.3 Procedures for Unblinding ................................ ................................ ................ 42
6.4 IMP Com pliance ................................ ................................ ............................... 42
6.5 Concomitant Therapy ................................ ................................ ........................ 42
6.5.1 COVID -19 Vaccine ................................ ................................ .......................... 44
6.6 Dose Modificat ion................................ ................................ ............................ 45
6.7 Interven tion After the End of the Study ................................ ............................. 45
7 DISCONTINUATION OF I MP AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL ................................ .......................... [ADDRESS_904707] to Follow -up................................ ................................ ............................. 46
7.4 Study  Suspensio n/Early Terminat ion................................ ................................ 47
8 STUDY ASSESSMENTS AN D PROCEDURES ................................ ............. 47
8.1 Efficacy Assessments ................................ ................................ ........................ 48
8.1.1 Moni toring COVID -19 Symptoms ................................ ................................ ....48
8.1.2 Severe or Critical Criteria ................................ ................................ ................. 49
8.1.3 Illness Visit s................................ ................................ ................................ .....50
8.1.4 SARS -CoV -2 Testing and Other Virology  Assessments ................................ ....50
8.1.5 Digital Heal th Device ................................ ................................ ....................... 50
8.1.6 Illness e -Diary................................ ................................ ................................ ..51
8.2 Safety Assessments ................................ ................................ ........................... 51
8.2.1 Physical Examinat ions................................ ................................ ...................... 51
8.2.2 Vital Signs................................ ................................ ................................ ........ 52
8.2.3 Electrocardiograms ................................ ................................ ........................... 52
8.2.4 Clinical Safety  Laboratory  Assessments ................................ ............................ 52
[IP_ADDRESS] Females Only ................................ ................................ ................................ ....[ADDRESS_904708] ion................................ ................................ .................... 54
[IP_ADDRESS] Moni toring After IMP Administration ................................ ............................... [ADDRESS_904709] ................................ ................................ ....57
8.3.5 Medically  Attended Adverse Events ................................ ................................ .57
8.3.6 Adverse Events Based on Signs and Symptoms ................................ ................ 58
8.3.7 Adverse Events Based on Examinat ions and Tests ................................ ............ 58
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 8of 1168.3.8 Hy’s Law ................................ ................................ ................................ .......... 58
8.3.9 Reporting of Serious Adverse Events ................................ ................................ 59
8.3.10 Pregnancy ................................ ................................ ................................ ......... 59
[IP_ADDRESS] Materna l Exposure ................................ ................................ ............................ 60
[IP_ADDRESS] Paternal  Exposure ................................ ................................ ............................. 60
8.3.11 Medicat ion Error ................................ ................................ ............................... 61
8.3.12 Device Deficiencies ................................ ................................ .......................... 61
8.4 Overdose ................................ ................................ ................................ .......... 61
8.5 Hum an Bi ological  Samples ................................ ................................ ............... 62
8.5.1 Pharmacokinet ics Assessments ................................ ................................ ......... 62
[IP_ADDRESS] Determinat ion of Drug Concentration ................................ ............................... 63
8.5.2 Immunogenicit y Assessments ................................ ................................ ........... 63
[IP_ADDRESS] Anti-drug Ant ibody  Assessments ................................ ................................ ......63
[IP_ADDRESS] SARS -CoV -2 Serol ogy Assessments ................................ ................................ 64
[IP_ADDRESS] Assessment of Mucosal Responses ................................ ................................ ...64
[IP_ADDRESS] Addit ional Serum Immunogenicit y................................ ................................ ...64
8.5.3 Pharmacodynamics ................................ ................................ ........................... 64
[IP_ADDRESS] SARS -CoV -[ADDRESS_904710] ion of mandatory  samples for bio marker analysis ................................ ...64
[IP_ADDRESS] Virologic Assessments ................................ ................................ ...................... 65
[IP_ADDRESS] Assessment of Viral Shedding ................................ ................................ .......... 65
8.6.2 Other Study -related Bi omarker Research ................................ .......................... 65
8.7 Medical Resource Utilizat ion and Healt h Economics ................................ ........ 65
9 STATISTICAL CONSIDER ATIONS ................................ ............................... 65
9.1 Statistical Hypotheses ................................ ................................ ....................... 65
9.2 Sample Si ze Determinat ion................................ ................................ ............... 66
9.3 Popul ations for Analyses ................................ ................................ .................. 66
9.4 Statistical Analyses ................................ ................................ ........................... 67
9.4.1 General Considerations ................................ ................................ ..................... 68
9.4.2 Efficacy ................................ ................................ ................................ ............ 69
[IP_ADDRESS] Primary Endpo int................................ ................................ .............................. 69
[IP_ADDRESS] Secondary  Endpo int(s)................................ ................................ ...................... 70
[IP_ADDRESS] Exploratory  Endpo int(s)................................ ................................ .................... 70
9.4.3 Safety................................ ................................ ................................ ............... 70
[IP_ADDRESS] Primary Endpo int(s)................................ ................................ .......................... 70
[IP_ADDRESS] Other Safet y Endpo int(s)................................ ................................ .................. 71
9.4.4 Pharmacokinet ic and Ant i-drug Ant ibody ................................ ......................... 71
[IP_ADDRESS] Pharmacokinet ic................................ ................................ ............................... 71
[IP_ADDRESS] Anti-drug Ant ibody ................................ ................................ .......................... 71
9.4.5 Methods for Multiplicit y Control ................................ ................................ ......72
9.4.6 Sensit ivity Analyses ................................ ................................ .......................... 72
9.4.7 Subgroup Analyses ................................ ................................ ........................... 72
9.5 Interim Analyses ................................ ................................ ............................... 72
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 9of 1169.[ADDRESS_904711] ivities: Treatment and Fo llow-up Peri od –Main Study ....[ADDRESS_904712] ivities: Illness Visits (Participants with Qualifying 
Clinical Symptoms) ................................ ................................ ................. [ADDRESS_904713] OF APPENDICES
Appendix A Regulatory , Ethical , and Study  Oversight Consi derati ons......................... 74
Appendix B Adverse Events: Definit ions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting ................................ ................................ ........ 80
Appendix C Handling of Human Bio logical  Samples ................................ .................. 85
Appendix D Actions Required in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law ................................ ................................ ........... 87
Appendix E Anaphylaxis ................................ ................................ ............................. 93
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 10of 116Appendix F e-Diary................................ ................................ ................................ ....97
Appendix G ECOG Performance Status ................................ ................................ .....105
Appendix H Abbreviat ions................................ ................................ ........................ 106
Appendix I Protocol  Amendment Hi story ................................ ................................ .109
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 11of 1161 PROTOCOL SUMMARY
1.1 Synopsis
Protocol Title :A Phase III Rando mized, Double -blind, Placebo -controlled, Mult i-center 
Study  in Adults to Determine the Safet y, and Efficacy o f AZD7442, a Combinat ion Product of 
Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post -exposure Prophylaxis of 
COVID -19
Short Title : A Phase III Doubl e-blind, Placebo -controlled Study  of AZD7442 for 
Post-exposure Prophylaxis o f COVID -19 in Adult s
Rationale : AZD7442, a combination o f 2 mAbs (AZD8895 and AZD1061) is being evaluated 
for the prevent ion or treatm ent of Coronavirus Disease 2019 (COVID -19). This Phase III 
study  will assess the efficacy o f AZD7442 for the post -exposure prophylaxis of COVID -19 in 
Adul ts.
Objectives and Endpoints:
Objective Estimand Description/Endpoint
Primary
To estimate the efficacy of a single IM 
dose of AZD7442 compared to placebo 
for the prevention of COVID -19 Population: Full analy sis set
Endpoint: A binary response, whereby a participant is defined as a 
COVID -[ADDRESS_904714] dose of IMP and prio r to Day 183 .
Intercurrent events: For participants who become unblinded to prop erly 
consider vaccination for COVID -19, take COVID -[ADDRESS_904715] prior to having met the criteria for the 
primary  efficacy  endpoint, data will be collected and analyzed regardless 
(ie, intercurrent events will be handled u sing treatment policy strategy).
Summary measure: Prophylactic efficacy, calculated as 1 -relative risk. 
(Relative risk is the incidence of infection in the AZD7442 group relative 
to the incidence of infection in the control group ).
To assess the safety and tolerability of a 
single IM dose of AZD7442 compared to 
placeboAEs, SAEs, MAAEs, and AESIs post dose of IMP .
Key Secondary
To estimate the efficacy of a single IM 
dose of AZD7442 compared to placebo Population: Full analy sis set
Endpoint: The incidence of SARS -CoV-2 RT -PCR-positive severe or 
critical symptomatic illness occurring after dosing with IMP.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 12of 116Objective Estimand Description/Endpoint
for the prevention of severe or critical 
symptomatic COVID -19Intercurrent events: For participants who become unblinded to properly 
consider vaccination for COVID -19,take COVID -[ADDRESS_904716] prior to having met the criteria for this 
endpoint, data will be collected and analyzed regardless (ie, intercurrent 
events will be handled using treatment policy strategy).
Secondary
To estimate the efficacy of a single IM 
dose of AZD7442 compared to placebo 
for the prevention of SARS -CoV -[ADDRESS_904717] -treatment response 
(negative at baseline to p ositive at any time post -baseline) for SARS -
CoV-2 nucleocapsid antibodies.
To estimate the efficacy of a single IM 
dose of AZD7442 compared to placebo 
for the prevention of COVID -19-related 
deathThe incidence of COVID -19-related death occurring after dosing with 
IMP.
To estimate the efficacy of a single IM 
dose of AZD7442 compared to placebo 
for the prevention of all -cause mortalityThe incidence of all -cause mortality occurring after dosing with IMP .
To assess the pharmacokinetics of 
AZD7442 adminis tered as a single dose 
of 300 mg IMSerum AZD7442 concentrations.
PK parameters if data permit .
To evaluate ADA responses to AZD7442 
in serumIncidence of ADA to AZD7442 in serum.
ADA, antidrug antibody; AE, adverse event; AESI, adverse event of special interest; COVID -19, coronavirus 
disease 2019; PK, pharmacokinetic; IM, intramuscular; IMP, investigational medicinal product; MAAE, 
medically attended adverse event; RT -PCR, reverse transcriptase polymerase chain reaction; SAE, serious 
adverse event; SARS -CoV-2, severe acute respi[INVESTIGATOR_7686] -coronavirus -2.
For Exploratory  objectives, see Section 3.
Overall Design:
This is a Phase III, randomized, doubl e-blind, placebo -controlled, mult i-center study  assessing 
the safet y and efficacy of a single dose of AZD7442 (× [ADDRESS_904718] ions) co mpared to placebo 
for the prevent ion of COVID -19. Approximately  100 si tes will  parti cipate in this study .
Parti cipants will be adults ≥[ADDRESS_904719] ion, symptomat ic 
or asymptom atic, who are therefore at appreciable risk of imminent ly developi[INVESTIGATOR_35910] -19, 
based on available risk assessment at time of enro llment (see Section 5.1). Parti cipants will be 
enrolled into one of 2 cohorts:
Cohort 1: Adults ≥ 60 y ears of age, living in lo ng-term care facilit ies. In this context, 
long-term care facilit ies include skilled nursing facilit ies, assisted living facilit ies, and 
independent living facilit ies for senior adults. 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 13of 116Cohort 2: Other adults ≥[ADDRESS_904720] itutional residences (military  lodging, 
dormi tories, etc.), household co ntacts, health care workers, long -term care facilit y 
workers, and workers in occupational or industrial settings in which close contact [CONTACT_670067] n. 
The first 15 participants (Sentinel Cohort) will undergo safet y monitoring for [ADDRESS_904721] IMP administration. 
Approximately  1125partici pants will be randomized in a 2:1 ra tio to receive a single dose (× 
[ADDRESS_904722] ions) of eit her 300 mg o f AZD7442 (n =approximately 750) or saline pl acebo 
(n=approximately  375) on Day  1. 
Following a screening evaluat ion, on the same day participants will receive a single dose (× [ADDRESS_904723] ions) of IMP . After administration of the dose of IMP on Day 1, parti cipants will 
undergo fo llow-up unt il Day 457. 
Disclosur e Statement: This is a para llel-group prevent ive study  with 2 arms that 
isdouble -blind.
Number  of Participants: Enrollment of up to [ADDRESS_904724].
Note : ‘Enrolled ’ means a participant ’s, or thei r legally  acceptable representative ’s, agreement 
to parti cipate in a clinical study  following com pletion of the informed consent process. 
Potenti al parti cipants who are screened for the purpose of determining elig ibilit y for the study , 
but are not randomly assigned in the study , are consi dered ‘screen failures ’. 
Intervention Gr oups and Duration: Participants will be randomized in a 2:1 ratio to receive 
one single 300 mg dose of AZD7442 (divided in [ADDRESS_904725] ions, one for each mAb 
component) or saline placebo. Invest igational medicinal product will be administered on 
Day 1, and parti cipants will be m onitored until  Day  457.
Data Safety Monitoring Board : An independent DSMB will review available safet y and
efficacy data after the first [ADDRESS_904726]. Enrollment will not be paused pending the DSMB ’s 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 14of 116review . Thereafter, the DSMB will review available safet y and efficacy d ata m onthly until the 
study  is stopped. During the study , the benefit/risk assessment will be cont inuously mo nitored 
by [CONTACT_670068].
If the study  is suspended and does not proceed following evaluat ion of cumulat ive safety data 
from the first [ADDRESS_904727] participant dosed, a 
protocol  amendment will  be submi tted to Heal th Authorities.
Statistical Methods
Primary Endpoint: The primary efficacy endpo int is a binary response, wh ereby a 
participant is defined as a COVID -[ADDRESS_904728] dose of IMP  and pri or to Day  183.
Sample Size: Approximately  1125 participants will be rando mized in a 2:1 ratio to receive a 
single IM dose of AZD7442 (divided into 2 sequential injections, one for each mAb 
component) (the active group, n = approximately  750) or saline placebo (divided into [ADDRESS_904729] ions) (the control group, n = approximately 375) on Day  1.
The samp le size calculat ions are based on the primary  efficacy endpo int and were derived 
following a modified Poisson regressio n approach (Zou 2004 ). The primary efficacy analysis 
will be conducted [ADDRESS_904730] approximately  90% power to demonstrate that the lower bound of the 2-sided 95% CI for 
efficacy is greater than zero, assuming an attack rate of 4.5% in the placebo group and true 
efficacy of 75% (equating to an attack rate of 1.1% in the AZD7224 group). All participants 
will be fo llowed f or the enti re durati on of  the stud y. 
1.2 Schematic
Figure 1 Study Design
aPrimary  analy sis to be conducted 30 days after the 25thevent is observed.
Note: An independent DSMB will review available safety and efficacy data after the first [ADDRESS_904731]. Enrollment will not be paused 
pending the DSMB’s review.

Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 15of 1161.3 Schedule of Activities
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 16of 116Table 1 Schedule of Activities: T reatment and Follow -up Period –Main Study 
Procedure Screen and
RandomizationFollow -up Period Early 
Discontinua
tion visitFor 
details, 
see 
section:Day 1 8 29 58 92 183 366 457
Window (days) NA ± 3 ± 3 ± 3 ± 5 ± 10 ± 15 ± 15
Informed consent X (predose) 5.1
Assignment SID number X (predose) 5.[ADDRESS_904732] had potential exposure within 8 
days prior to Day  1aX
Verify  eligibility  criteria X (predose) 5.1
Demographics and Risk Categorization X (predose) 5.1
Medical history and Functional StatusbX (predose)
Complete physical examination, 
including height and weightX (predose)8.2.1
Targeted physical examination X X X X X X X 8.2.1
Vital signs (including pulse oximetry) X (pre and post 
dose)cX X X X X X X 8.2.2
Triplicate 12 -lead ECG X (predose) X X 8.2.[ADDRESS_904733] -urine (WOCBP only)dX (predose) XdXdXdXdXdXdXd8.2.4.1
FSH (suspected postmenopausal 
women, <50 years)eX (predose) [IP_ADDRESS]
Completed rapid point of care SARS -
CoV-2 serology testing using serum 
sampleX (predose)[IP_ADDRESS]
Serum chemistry X (predose)fX X X X X X X 8.2.4
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 17of 116Table 1 Schedule of Activities: T reatment and Follow -up Period –Main Study 
Procedure Screen and
RandomizationFollow -up Period Early 
Discontinua
tion visitFor 
details, 
see 
section:Day 1 8 29 58 92 183 366 457
Window (days) NA ± 3 ± 3 ± 3 ± 5 ± 10 ± 15 ± 15
Hematology X (predose)fX X X X X X X 8.2.4
Urinaly sis X (predose)fX X X X X X X 8.2.4
Coagulation X (predose)f8.2.4
Concomitant medications X (predose) X X X X X X X 6.5
IMP administration X 6.1
Efficacy assessments
Weekly telephone/email/text contacts -
monitoring for COVID -19 qualifying 
symptomsg8.1.1
NP swab for SARS -CoV-2 RT -PCR 
(central laboratory)X (predose) [IP_ADDRESS]
Serum sample for SARS -CoV-2 
serology (anti -nucleocapsid) testing X (predose) X X X X X X X [IP_ADDRESS]
Pharmacokinetics, pharmacodynamics, and ADA assessments
Serum sample for AZD7442 
pharmacokinetic assessmentX(predose) X X X X X XX
[optional]X 8.5.1
Serum sample for AZD7442 ADA 
assessmentX
(predose)X X X XX 
[optional]X [IP_ADDRESS]
Serum sample for SARS -CoV-2 nAbs
assessmentX
(predose)X X X X X XX 
[optional]X [IP_ADDRESS]
Serum sample exploratory biomarkers X
(predose)X X X X X X X [IP_ADDRESS]
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 18of 116Table 1 Schedule of Activities: T reatment and Follow -up Period –Main Study 
Procedure Screen and
RandomizationFollow -up Period Early 
Discontinua
tion visitFor 
details, 
see 
section:Day 1 8 29 58 92 183 366 457
Window (days) NA ± 3 ± 3 ± 3 ± 5 ± 10 ± 15 ± 15
Nasal adsorption for PK exploratory 
assessmentshX X X X X X X [IP_ADDRESS]
Safety assessments
Check injection sitesiX 8.2.[ADDRESS_904734] for safety 
monitoringk8.3
aSee Inclusion criterion 2 for further details: Long -term care facilities; industrial setting; military setting; health care facility; university; college dormitories; 
household contact; other high -density inter -personal proximity. Exposure within 8 days sh ould be confirmed, and investigator attestation that they were able 
to confirm the details of the potential exposure is required. Confirmation should be made either directly through the partici pant’s medical record or via 
official documentation from anothe r source attesting to exposure (eg, letter from employer, notification from local health department, etc). A verbal/written 
statement from the participant, without independent substantiation, is not acceptable.bECOG performance recorded at baseline only ( Appendix G).cVitals signs should be performed predose and 15 minutes (± 5 minutes) after both injections are complete.dIf urine tests positive or indeterminate, a quan titative serum β -hCG will be performed for confirmation.eFSH will be analyzed at the screening visit to confirm postmenopausal status only in women < [ADDRESS_904735] been am enorrhoeic for ≥ 12 
months. U ntil FSH is documented to be within menopausa l range, the participant is to be considered of childbearing potential. For women aged ≥ 50 years, 
postmenopausal is defined as having a history of ≥ [ADDRESS_904736] supplies are available sampling should be performed. iPerform immediately, 30 minutes ( ± 10 minutes) after both injections are complete, and prior to participant release.jThe first [ADDRESS_904737]. All other 
participants will be co ntacted weekly. 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 19of 116lAt Day  457 AE/SAE/MAAE/AESI assessment may be made by [CONTACT_756]. 
Ab, antibody; ADA, antidrug antibody; AE, adverse event; AESI, adverse event of special interest; β -hCG, beta -human chorionic gonadotropin; MAAE, 
medically attended adverse event; NA, not applicable; nAb, neutralizing antibody ; RT-PCR, reverse transcriptase polymerase chain reaction; SAE, serious 
adverse event; SARS -CoV-2, severe acute respi[INVESTIGATOR_7686] -coronavirus -2; US, [LOCATION_002]; WOCBP, women of childbearing potent ial.
Table2 Schedule of Activities: Illness V isits (Participants with Qualifying Clinical Symptoms)
ProcedureaSite Visit Home/Self Collection by [CONTACT_670069] -CoV -2 Positive 
Participants Onlyc For 
details, see 
section:DaybIL-D1 IL-D3 IL-D5 IL-D8 IL-D11 IL-D14 IL-D21 IL-D28
Window (days) NA ± 1 ± 1 ± 2 ± 2 ± 2 ± 2 ± 2
Medical history X X X X
Brief phy sical examination X X X X 8.2.1
Vital signs (including pulse oximetry) X X X X 8.2.2
Triplicate 12 -lead ECG X 8.2.3
Concomitant medication 6.5
Efficacy assessments
Digital health deviced8.1.5
Symptoms associated with COVID -19
(recorded daily by [CONTACT_670070] 
e-Diary )e8.1.6
Self-collected anterio r nasal swab for viral 
sheddingeX X X X X X X X [IP_ADDRESS]
Nasopharyngeal swab
SARS -CoV -2 RT -PCR (local laboratory)fX [IP_ADDRESS]
SARS -CoV -2 RT -PCR (central laboratory), 
sequencing, respi[INVESTIGATOR_670033] X X X [IP_ADDRESS]
Immunogenicity, Pharmacodynamics, and Pharmacokinetics
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 20of 116Table2 Schedule of Activities: Illness V isits (Participants with Qualifying Clinical Symptoms)
ProcedureaSite Visit Home/Self Collection by [CONTACT_670069] -CoV -2 Positive 
Participants Onlyc For 
details, see 
section:DaybIL-D1 IL-D3 IL-D5 IL-D8 IL-D11 IL-D14 IL-D21 IL-D28
Window (days) NA ± 1 ± 1 ± 2 ± 2 ± 2 ± 2 ± 2
Serum sample for AZD7442 PK assessment X X X 8.5.1
Serum sample for SARS -CoV-2 nAbs 
assessmentX X X [IP_ADDRESS]
Nasal adsorption for SARS -CoV-2 mucosal 
responses and exploratory assessmentsgX X X [IP_ADDRESS]
Serum sample for exploratory assessments X X X [IP_ADDRESS]
Safety assessments
SAEs, MAAEs, and AESIs 8.[ADDRESS_904738] epi[INVESTIGATOR_670034] 1 = 1 IL-D1, Illness Visit Day 3 = 1IL -
D3 etc, and for the second epi[INVESTIGATOR_1865] 2 IL-D1, 2IL -D3 and so on as applicable.cWhere supported, home or mobile visits by [CONTACT_670071].dDigital health device: A wearable health device with biosensor. Measures will include skin temperature, heart rate, respi[INVESTIGATOR_31145], blood oxygen 
saturatio n, and phy sical activity.eParticipants unable to self -collect are excluded from this assessment.fIf an immediate test result is not available the participant should continue with the Illness Visit schedule until their resu lt has been confirmed. Only if the 
local laboratory result is unavailable should the central laboratory result be used.gWhen test supplies are available sampling should be performed. 
Note: The Illness Visit schedule is to be performed in addition to the Main St udy Visit schedule, where visits coincide all assessments from the Main Study 
schedule and Illness Visit schedule should be performed.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 21of 116Table2 Schedule of Activities: Illness V isits (Participants with Qualifying Clinical Symptoms)
ProcedureaSite Visit Home/Self Collection by [CONTACT_670069] -CoV -2 Positive 
Participants Onlyc For 
details, see 
section:DaybIL-D1 IL-D3 IL-D5 IL-D8 IL-D11 IL-D14 IL-D21 IL-D28
Window (days) NA ± 1 ± 1 ± 2 ± 2 ± 2 ± 2 ± [ADDRESS_904739]; COVID -19, c oronavirus disease 2019; D, day; ECG, electrocardiogram; MAAE, medi cally attended adverse event; 
NA, not applicable; nAb, neutralizing antibody; NP , nasophary ngeal; PK, pharmacokinetic; RT -PCR, reverse transcriptase polymerase chain reaction; SAE,
serious adverse event; SARS -CoV-2,severe acute respi[INVESTIGATOR_7686] -corona virus -2.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 22of 1162 INTRODUCTION
SARS -CoV-2 is the causat ive agent of the ongoing COVID -19 pandemic that, as of 
29September 2020, has resulted in 33,206,004 confirmed cases of COVID -19, including 
999,239 deaths, reported to WHO (WHO 2020 ). Unlike the majorit y of coronaviruses that 
cause mild disease in humans and animals, SARS -CoV-[ADDRESS_904740] ic of the genetically -similar SARS -CoV and the more distantly related 
MERS -CoV, both of which were responsible for prior outbreaks in 2002 to 2003 and 2012, 
respectively  (Gorbalenya et al 2020 ).
Effective interventi ons to prevent or treat COVID -19 rem ain limited in number and clinical 
experience is limited. Clinical management is limited to supportive care, consequent ly 
overwhelming resources of healt hcare systems around the world.
As a response to the ongoing pandemic, [COMPANY_008] is developi[INVESTIGATOR_198607] -CoV-2 
S protein. The SARS -CoV-2 spi [INVESTIGATOR_198608] ’s RBD, which enables the virus 
to bind to receptors on hum an cells. By  [CONTACT_670072] n of the virus's spi[INVESTIGATOR_144870], 
antibodies can block the virus ’s attachm ent to human cells, and, therefore, is expected to block 
infect ion. Amino acid subst itutions have been introduced into the ant ibodies to both extend 
their half -lives, which should prolong their potential prophylact ic benefit, and decrease Fc 
effector funct ion in order to decrease the potential risk of ant ibody -dependent enhancement of 
disease.
AZD7442, a combinat ion of 2 of these mAbs (AZD8895 and AZD106 1), is being evaluated 
for administrati on to prevent and/or treat COVID -19. There is currently one ongoing Phase I 
study  with AZD7442.
For further details, please refer to the AZD7442 IB.
2.1 Study Rationale
AZD7442, a combinat ion of 2 mAbs (AZD8895 and AZD106 1) is being evaluated for 
administration to prevent or treat COVID -19. This Phase III study will assess the efficacy o f 
AZD7442 for the post -exposure prophylaxis of COVID -[ADDRESS_904741] cells during coronavirus 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 23of 116infect ion via different receptors (Li 2016 ). SARS -CoV-2 belongs to the phylogenet ic lineage 
B of the genus Beta -coronavirus and it recognizes the ACE2 as the entry  receptor (Zhou et al 
2020 ). Itis the seventh coronavirus known to cause human infect ions and the third known to 
cause severe disease after SARS -CoV and MERS -CoV.
2.2.[ADDRESS_904742] ion by [CONTACT_99213]7742 in vitro, wit h half -maxima l inhibitory  concentrati on 
(IC50) values between 10 and 26 ng/mL. 
A combinat ion mAb approach, like AZD7442, is advantageous because SARS -CoV-[ADDRESS_904743] itutions to extend t 1/2and reduce Fc effector function, respect ively. These 
subst itutions resulted in an expected increase in binding affinit y to FcRn at pH 6.[ADDRESS_904744] itutions did not al ter 
the potency  of AZD7442 in vitro. 
The parental mAbs of AZD8895 (COV2 -2196) and AZD1061 (COV2 -2130), whi ch lack Fc 
subst itutions, provided protecti on from SARS -CoV -[ADDRESS_904745] ic 
administration of the mAbs alone or in combinat ion, at a 10  mg/kg dose, resulted in attenuated 
weight loss, as well  as reduced vi ral RNA levels in the l ungs of mice challenged wit h 
SARS -CoV -2. Similarly, r educed vi ral RNA levels were measured in the lungs of mice 
when mAbs were administered 12 hours after infection at a 20 mg/kg dose. The reduction in 
viral t iters correlates with a reduction in pro inflammatory cytokines and alveo lar damage in 
the lungs of i nfected mice. 
Finally , intravenous administration of AZD7442 protected rhesus macaques fro m 
SARS -CoV-[ADDRESS_904746] ion demonstrated mean viral sgmRNA  in nasal  mucosae and bronchoalveol ar lavage that 
peaked at approximately 5 log10 copi[INVESTIGATOR_014]/swab or 5 log10 copi[INVESTIGATOR_014]/mL, respect ively . In contrast, 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 24of 116NHPs prophylaxed with eit her a 4 or 40 mg/kg dose of AZD7442 had little or no detectable 
levels o f viral sgmRNA  in both nasal mucosae and lungs. In t he treatment group of the study , 
intravenous administration of a 40 mg/kg dose of AZD7442 one day  after SARS -CoV-[ADDRESS_904747] a similar 
[COMPANY_008] -devel oped mAb, MEDI8897 (nirsevimab). Similar to AZD8895 and AZD1061, 
MEDI8897 is a human IgG1 κ mAb directed against a viral fusio n protein (F protein of RSV) 
and contains the YTE amino acid subst itutions in it s Fc region to prolong its t 1/2. Unlike 
MEDI8897, AZD8895 and AZD1061 additionally contain a second triple amino acid 
subst itution, L234F/L235E/P331S (TM), in their Fc regions, intended to inhibit Fc γR binding. 
Following IV injection in Tg32 mice, the PK of MEDI8897+TM was similar to that of 
MEDI8897, indicat ing the TM did n ot significant ly affect the PK of MEDI8897. The PK of 
AZD8895 and AZD1061 were similar to those of MEDI8897 and MEDI8897+TM. In the 8 -
week cyno molgus monkey GLP toxico logy study  for AZD7442, high exposures were 
achieved and were consistent across animals and between m ales and females for both 
AZD8895 and AZD1061, for both the 300 mg/kg IV dose and the 75 mg/kg IM dose. The 
exposures were as expected since the AZD7442 TK was similar to the TK of nirsevimab in 
cyno molgus monkeys based on [ADDRESS_904748] ional potency  data 
(virus-neutralizing act ivity of AZD7442 against SARS -CoV-2) and PK data. In addit ion, a 
viral dynamic model was developed, which allowed f or understanding of the 
pharmacodynamic effects of AZD7442 to i nhibit a SARS -CoV-2 infection and the result ing 
immune response. The viral dynamic model indicates that virus entry  inhibit ion greater than 
approximately  80% is sufficient to prevent infect ion. Therefore, doses were selected that result 
in concentrati ons in serum and the ELF of the lungs above the in vitro derived inhibit ion 
param eter of IC 80(inhibit ing SARS -CoV-2 by 80%) of  104 ng/mL  for a durati on of  at least [ADDRESS_904749] dose. Assuming a parti tion rati o of 1% f or lung ELF -to-serum  and the IC 80of 104 
ng/mL, an IM dose of [ADDRESS_904750] ion with significant reducti on in
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 25of 116peak viral load and complete suppressio n of viral load earlier than acco mplished by  [CONTACT_670073] .
The doses tested in the monkey toxico logy study  (75 m g/kg per ant ibody  for IM and 
300mg/kg per ant ibody  for IV) were determined to be n o-observed -adverse -effect level 
(NOAELs). These NOAELs were used to calculate the safety margins for the clinical doses in 
the FTIH study  (Study  D8850C00001) by [CONTACT_670074] (C max or AUC) 
over the first [ADDRESS_904751] dose in the monkeys by [CONTACT_670075] (C max or 
AUC) over the first [ADDRESS_904752] dose for each clinical dose cohort. The calculated margins 
using eit her AUC or C max are shown in Table3for the IM clinical dose relat ive to the IM 
NOAEL  and for the IV clinical doses relative to the IV NOAEL.
Table3 Safety Margin Pr ediction for  the Dose Levels in Phase I Study 
D8850C00001
Route of 
Administration in 
FTIHFTIH AZD7442 
Dose (mg)GLP Monkey 
Toxicology Study 
AZD7442 Dose 
(mg/kg)Safety Margin 
AUC (0 -60 days)Safety Margin 
Cmax
IM 300 150 33 62
IV 300 600 67 150
IV 1000 600 22 49
IV 3000 600 7.5 16
AUC, area under plasma concentration -time curve; C max, maximum plasma concentration; FTIH, first -time-in-
human; GLP, Good Laboratory Practice; IM, intramuscular; IV, intravenous; mAb, monoclonal antibody. 
2.2.3 Summary of Toxicology
Due to the foreign nature of the spi[INVESTIGATOR_670035] 2 antibodies in AZD7442 
and lack of spi[INVESTIGATOR_670036] n in human or animal t issues, no pharmaco logically 
relevant speci es is available for nonclinical safet y testing o f AZD7442. Therefore, in 
accordance with ICH ◦S6◦(R1), only a short term, ie, a single IV and IM dos e, study  of the 
combinat ion (AZD7442) in cyno molgus monkeys with a 2 -and 8 -week fo llow-up, and a TCR 
study  assessing binding of the combinat ion (AZD7442) and the individual ant ibodies 
(AZD8895 and AZD1061) to the full list of human and cyno molgus monkey t issues are being 
conducted. The single dose study in cyno molgus mo nkeys is ongo ing, and interim result 
summaries are available for W eek 2 and W eek 8 (end of study ). At the W eek [ADDRESS_904753] ion site 
observat ions/derm al scoring, body  weights, qualitative food consumpt ion, ophthalmo logy, 
veterinary  physical  examinat ions, ECGs, neurologic examinat ions, blood pressure and heart 
rate, respi[INVESTIGATOR_670037], body  temperature, clinical pathology  parameters (hematology , 
coagul ation, and urinalysis/urine chemistry ), gross necropsy  findings, organ weights, or 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 26of 116histopathologic examinat ions. Based on the W eek 2 assessment, the single dose administration 
of AZD7442 via intravenous infusio n was well tolera ted in cyno molgus mo nkeys at a dose 
level of 600 mg/kg (combinat ion of 300 mg/kg of AZD8895 and 300 mg/kg of AZD1061). A 
limited summary of the available W eek 8 end of study  data covering clinical signs, body  
weight, clinical pathol ogy, organ wei ghts, and macroscopic findings at necropsy , confi rms the 
tolerabilit y demo nstrated at the W eek 2 interim assessment. In the TCR study , the assessment 
of the combinat ion (AZD7442), and the individual components AZD8895 and AZD1061, was 
completed on the full list of t issues from 3◦independent human and cyno molgus mo nkey 
donors. No binding to any  tissues was observed, confirming the absence of target and off -
target binding in humans and cyno molgus mo nkeys.
Adetailed description o f the chemistry , pharm acology , efficacy ,and safet y of AZD7442 is 
provi ded in the AZD7442 IB.
2.3 Benefit/Risk Assessment
More detailed informat ion about the known and expected benefits and potential risks of 
AZD7442 can be found in the AZD7442 IB.
2.3.[ADDRESS_904754] ion site reactions, infusio n-related 
reacti ons, and ADE disease.
Clinical Study Prot ocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 27of 116Antibody -dependent enhancement of disease is a theoretical risk. T wo different syndro mes 
exist: 1) ADE, which invo lves increased binding efficiency o f virus -antibody  com plexes to Fc 
receptor bearing cells and which triggers virus entry . The mAbs in AZD7442 have been 
designed with a modificat ion to prevent binding to cellular Fc receptors, so the ris k of ADE 
occurring via this mechanism should range fro m very low to none. 2) V AERD, which is a 
distinct clinical syndrome that occurred in young children in the 1960s when who le 
inact ivated virus vaccines for measles and RSV were tested. Immunizing wit h limiting doses 
of RSV ant igen, especially with conformat ionally incorrect antigens, can result in 2 major 
types of  immuno logical phenomena: a) A relatively  high rati o of antibody  that binds, but does 
not neutralize, virus could potentially result in immunoge nic cell death and co mplement 
activat ion (leading to inflammat ion and airway obstruction); b) immunization wit h who le 
inact ivated virus vaccines can result in allergic inflammat ion characterized by , eg, increased 
mucus production, airway  hyperresponsivenes s, and attenuated cy tolytic T cell act ivity (T 
helper 2 cell immune response). This mechanism, induced by [CONTACT_358877], should not be 
provoked by  [INVESTIGATOR_74241].
2.3.[ADDRESS_904755] any guaranteed benefit, however, AZD7442 may be 
efficac ious and offer participants protection from COVID -19. 
2.3.3 Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimize risk to participants in this study , the 
potenti al risks i dentified in associat ion with AZD7442 are just ified by [CONTACT_941] a nticipated benefits 
that may  be afforded to parti cipants at ri sk of COVID -19.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 28of 1163 OBJECTIVES AND ENDPO INTS
Table 4 Objectives and Endpoints
Objective Estimand Description/Endpoint
Primary
To estimate the efficacy of a single IM 
dose of AZD7442 compared to placebo 
for the prevention of COVID -19Population: Full analy sis set
Endpoint: A binary response, whereby a participant is defined as a 
COVID -[ADDRESS_904756] dose of IMP and prior to Day 183 .
Intercurrent events: For participants who become unblinded to prope rly 
consider vaccination for COVID -19, take COVID -[ADDRESS_904757] prior to having met the criteria for the 
primary  efficacy  endpoint, the data will be collected and analyzed 
regardless (ie, intercurrent events will be handle d using treatment policy 
strategy ).
Summary measure: Prophylactic efficacy, calculated as 1 -relative risk. 
(Relative risk is the incidence of infection in the AZD7442 group relative 
to the incidence of infection in the control group) .
To assess the safety and tolerability of a 
single IM dose of AZD7442 compared to 
placeboAEs, SAEs, MAAEs, and AESIs post dose of IMP .
Key Secondary
To estimate the efficacy of a single IM 
dose of AZD7442 compared to placebo 
for the prevention of severe or critical 
symptomatic COVID -19Population: Full analy sis set
Endpoint: The incidence of SARS -CoV-2 RT -PCR-positive severe or 
critical symptomatic illness occurring after dosing with IMP.
Intercurrent events: For participants who become unblinded to properly 
consider vaccination for COVID -19,take COVID -[ADDRESS_904758] prior to having met the criteria for this 
endpoint, data will be collected and analyzed regardless (ie, intercurrent 
events will be handled using treatment policy strategy).
Secondary
To estimate the efficacy of a single IM 
dose of AZD7442 compared to placebo 
for the prevention of SARS -CoV -[ADDRESS_904759] -treatment response 
(negative at baseline to p ositive at any time post -baseline) for SARS -
CoV-2 nucleocapsid antibodies.
To estimate the efficacy of a single IM 
dose of AZD7442 compared to placebo 
for the prevention of COVID -19-related 
deathThe incidence of COVID -19-related death occurring after dosing with 
IMP.
To estimate the efficacy of a single IM 
dose of AZD7442 compared to placebo 
for the prevention of all -cause mortalityThe incidence of all -cause mortality occurring after dosing with IMP.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 29of 116Table 4 Objectives and Endpoints
Objective Estimand Description/Endpoint
To assess the pharmacokinetics of 
AZD7442 administered as a single dose 
of [ADDRESS_904760]-treatment GMTs and GMFRs from baseline value through Day 457 
after single IM dose in SARS -CoV-2 neutralizing antibodies (wild -type 
assay  or pseudo neutralization assay).
To quantify SARS -CoV -2 viral loads in 
infected participants treated with a single 
IM dose of AZD7442 or placebo (Illness 
Visits)Viral genome copi [INVESTIGATOR_670038] -PCR.
To quantify duration of viral shedding in 
participants with symptomatic COVID -
19 treated with a single IM dose of 
AZD7442 or placebo (Illness Visits)Duration of SARS -CoV-2 shed ding in anterior nasal swabs over time. 
To characterize resistance to AZD7442 
(Illness Visits)Genoty pic analy sis and biochemical and/or susceptibility analysis of 
SARS -CoV -2 variants to AZD7442.
To assess symptoms associated with 
COVID -19 using an e -Diary  in 
participants treated with a single IM dose 
of AZD7442 or placebo (Illness Visits 
only)Symptoms recorded by [CONTACT_670076] e -Diary  from Illness 
Visits Day 2 through Day 28. 
To assess additional immune responses 
following a single IM dose of AZD7442 
or placeboOther exploratory assays for humoral, mucosal and cellular immune 
responses may be performed based upon emerging safety, efficacy, and 
pharmacodynamic data.
ADA, antidrug antibody; AE, adverse event; AESI, adverse event of special interest; COVID -19, coronavirus 
disease 2019; GMT, geometric mean titers, GMFR, geometric mean fold rises; IM, intramuscular; IMP, 
investigational medicinal product; nAb, neutralizin g antibody; NP, nasopharyngeal ; qRT -PCR, quantitative real -
time poly merase chain reaction; RT -PCR, reverse transcriptase polymerase chain reaction; SAE, serious adverse 
event; SARS -CoV-2, severe acute respi[INVESTIGATOR_7686] -coronavirus -2
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 30of 1164 STUDY DESIGN
4.1 Overall Design
This is a Phase III, randomized, double -blind, placebo -controlled, mult i-center study  assessing 
the safet y and efficacy of a single dose of AZD7442 ( ×[ADDRESS_904761] ions) co mpared to placebo 
for the prevent ion of COVID -19. Approximately  100 si tes will participate in this study . 
Parti cipants will be adults ≥[ADDRESS_904762] ion, symptomat ic 
or asymptom atic, who are therefore at apprecia ble ri sk of imminent ly developi[INVESTIGATOR_35910] -19, 
based on available risk assessment at time of enro llment (see Section 5.1). Parti cipants will be 
enrolled into one of 2 cohorts:
Cohort 1: Adults ≥ 60 y ears of age, living in lo ng-term care facilit ies. In this context, 
long-term care facilit ies include skilled nursing facilit ies, assisted living facilit ies, and 
independent living facilit ies for senior adults. In this cohort, “potential exposure to a 
specific ident ified individual wit h laboratory -confirm ed SARS -COV -2 infecti on" is 
defined to mean the occurrence of SARS -COV -[ADDRESS_904763] ion, symptomat ic or 
asymptomat ic, in another resident of the facilit y or in a staf f member of the facilit y.
Cohort 2: Other adults ≥[ADDRESS_904764] itutional residences (military  lodging, 
dormi tories, etc.), household contacts, health care workers, long -term care facilit y 
workers, and workers in occupational or industrial settings in which close contact [CONTACT_670067] n.
The first 15 participants (Sentinel Cohort) will undergo safet y monitoring for [ADDRESS_904765] IMP administration.
Up to 1125 participants will be rando mized in a 2:1 ratio to receive a single dose (× [ADDRESS_904766] ions) of eit her 300 mg of AZD7442 (n =approximately  750) or saline placebo 
(n=approximately  375) on Day  1. Enrollment will continue unt il the 25thprimary  endpoint 
event has been confirmed, or until [ADDRESS_904767]. F ormal efficacy assessment is intended at the primary  analysis, 30 days after the 25th
primary  endpoint has occurred. 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 31of 116Following a screening eva luation, on the same day participants will receive a single dose (× [ADDRESS_904768] ions) of IMP . After administration of the dose of IMP on Day 1, parti cipants will 
undergo fo llow-up as stated in the schedule of act ivities. All part icipants in the study  will b e 
assessed for efficacy wit h all data available through their last assessment up to visit Day [ADDRESS_904769] R T-PCR -confirmed SARS -CoV-2 and m eet the qu alifying 
symptoms (see Section 8.1.1 ). 
The efficacy endpo ints in this study  are designed to dem onstrate clinically meaningful benefit 
in prevent ing COVID in acutely exposed populat ions, in a safe manner . These definit ions have 
4 com ponents: (1) a definit ion of clinical illness; (2) a method of respi[INVESTIGATOR_670039] o f associ ated shedding of the relevant virus; (3) an assay me thod 
for laboratory  confirmat ion; and (4) a defined surveillance period.
The primary  efficacy analysis is to be conducted [ADDRESS_904770] -exposure setting, in which COVID -19 cases 
which will meet the primary  endpoint definit ion shoul d occur wi thin a brief period of time 
after an index case is ident ified. The incubat ion period for COVID -19 has been characterized 
as typi[INVESTIGATOR_670040] m 3 to 8 day s (Xie et al  2020 ). Therefore, primary transmissio n from 
an index case should be apparent within [ADDRESS_904771]. Preventing this outcome would result in significant benefit, and, in this 
study  popul ation, should be readily  measurable. 
4.3 Justification for Dose
The dose level, 300 mg IM, selected for this study  is based on PK and neutralizing t iter results 
of the Phase I study  of AZD7442, in which the 300 mg IM dose produced serum plaque 
reducti on neutralizing titer -80 levels ranging from  > 256 to > 1024. Neutralizing ant ibody  titer 
level in this range should be sufficient to prevent illness.
For further details, please refer to the AZD7442 IB.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 32of 1164.[ADDRESS_904772] com pleted the study  if he/she has co mpleted all phases of 
the study , including the last scheduled procedure shown in the SoA.
The end o f the study  is defined as the date of the last scheduled procedure shown in the SoA  
for the l ast parti cipant in the study  globally .
[ADDRESS_904773] a participant ’s safety , 
physical or mental integrit y, or sci entific value will be classif ied as a serious breach.
5.1 Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criteria apply:
Age
1Parti cipant m ust be ≥ [ADDRESS_904774] ion, symptomat ic or 
asymptomat ic, who are therefore at appreciable risk of imminent ly developi[INVESTIGATOR_382210] -19, based on available risk assessment at time of enrollment, within any o f the 
following settings:
Long -term care facilit ies, including skilled nursing homes, assisted living ho mes, 
independent living residences for the elderly. Residen ts, heal th care workers in such 
facilit ies, and other staff o f such facilit ies are eligible under this criterion. For 
participants entering the study  from these settings, “potential exposure to a specific 
ident ified individual wit h laboratory -confirmed SAR S-COV -2 infecti on" is defined 
to mean the occurrence of SARS -COV -[ADDRESS_904775] ion, symptomat ic or asymptomat ic, in 
another resi dent of the facilit y or in a staff member of the facilit y. 
Industri al setti ngs shown to have been at high risk for SARS -COV -2 transmi ssion, 
including but not limited to meatpacking plants. Workers in such facilit ies are 
eligible under this criterion.
Military  settings including but not limited to barracks, ships, or other close -quarters 
working environments. Military and civilian person nel exposed in such settings are 
eligible.
Health care facilit ies. Heal th care workers and other staff exposed in such setting are 
eligible under this criterion.
Universit y or college dormitories. Students exposed in such setting are eligible.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 33of 116Househo ld co ntacts. Any adult living in the same househo ld as an index case are 
eligible under this criterion.
Other settings of similar close or high -densi ty inter-personal proximit y. The potenti al 
for exposure in such settings may  be assessed on a case -by-case basis by 
[CONTACT_431]. Individuals exposed in such settings are eligible under this criterion.
3Prior to enrollment, participants must not have had COVID -19 symptoms, as described in 
Table 8, within 10 days of dosing. 
4Negative result fro m point of care SARS -CoV -2 serology  testing at screening. 
Reproduction
5Contraceptive use by [CONTACT_198654]:
(a)Male Parti cipants: Contraception for male participants is not required, however, to 
avoid the transfer of any fluids, all male part icipants m ust use a condom  from Day 1 
and agree to continue through 365 days fo llowing administration of the IMP. 
(b)Female Par ticipants
Women not of childbearing potential are defined as women who are either 
perm anent ly sterilized (hysterectomy, bilateral oophorectomy, or bilateral 
salpi[INVESTIGATOR_1656] ), or who are postm enopausal . Women will be considered 
postm enopausal if they  have bee n amenorrhoei c for [ADDRESS_904776] anned 
date of rando mizat ion without an al ternat ive medical cause. The fo llowing age -
specific requirements apply:
oWomen < [ADDRESS_904777] been 
amenorrhoei c for 12 m onths or m ore following cessation o f exogenous hormonal 
treatm ent and FSH l evels in the postm enopausal  range.
oWomen ≥[ADDRESS_904778] been 
amenorrhoei c for 12 m onths or more fo llowing cessation o f all exogenous 
horm onal treatm ent.
Female participants of childbearing potential must use one highly effect ive form of 
birth control. A highly effect ive method of contraception is defined as one that can 
achieve a failure rate of less than 1% per y ear when used consistently and correctly. 
Women of childbearing potential who are sexually active with a non -sterilized male 
partner m ust agree to use one highly effect ive method of birth control, as defined 
below, from Day [ADDRESS_904779] ration 
of the IMP. Cessation of contraception after this point should be discussed wit h a 
responsible physician. Periodic abstinence (calendar, symptothermal, post -ovulation 
methods), withdrawal (co itus interruptus), spermicides only, and lactational 
amenorrhea m ethod are not acceptable methods of contraception. Female condom 
and male condom should not be used together. All women of childbearing potential 
must have a negative serum pregnancy test result at Visit 1 and throughout the study  
as indicated per t he SoA (see Section 1.3).
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 34of 116Examples of highly  effect ive birth control methods are listed in Table5.
Table5 Highly Effective Methods of Contraception
Barrier Methods Hormonal Methods
• Intrauterine device
• Intrauterine hormone -releasing system 
(IUS) a
• Bilateral tubal occlusion
• Vasectomized partner b
• Sexual abstinence c• Combined (estrogen -and progestogen -containing 
hormonal contraception) associated with inhibition of 
ovulatio n
Oral (combined pi[INVESTIGATOR_4382])
Intravaginal
Injectable
Transdermal (patch)
• Progestogen -only hormonal contraception associated 
with inhibition of ovulation
Oral 
Injectable
Implantable
aThis is also considered a hormonal method.bProvided that partner is the sole sexual partner of the woman of childbearing potential study participant 
and that the vasectomized partner has received medical assessment of the surgical success. cSexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of the study and if it is the preferred and usual lifestyle of the 
participant.
Informed Consent
6Able to understand and co mply with study  requi rements/procedures (if app licable, with 
assistance by [CONTACT_84452], surrogate, or legally authorized representative) based on the 
assessment of the invest igator. 
7If able, signed informed consent. Ensure that participants who are considered by [CONTACT_670077] a legally acceptable representative show evidence o f assent, as 
applicable in accordance with local regulat ions. See Appendix Afor further details.
5.2 Exclusion Criteria 
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
1History  of laboratory -confirmed SARS -CoV -2 infection or SARS -CoV -2 seropositivit y at 
screening.
2History  of infecti on wi th severe acute respi[INVESTIGATOR_82326] e (SARS) or Mi ddle East 
respi [INVESTIGATOR_670041] (MERS).
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 35of 1163Known history  of allergy  or reacti on to any  com ponent of the study  drug form ulation.
4Previous hypersensit ivity, infusi on-related reacti on, or severe adverse reaction fo llowing 
administration of a mAb.
5Any pri or recei pt of  invest igational or licensed vaccine or other mAb/bio logic indicated 
for the prevent ion of SARS -CoV -2 or COVID -19 or expected receipt during the peri od of  
study  follow-up.
6Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet 
disorder), or pri or history  of significant bl eeding or brui sing fo llowing IM inject ions or 
venepuncture. 
7Any other significant disease, disorder, or finding that, in the judgement of the 
investigator, may significant ly increase the risk to the participant because of participation 
in the study , affect the abilit y of the parti cipant to parti cipate in the study , or impair 
interpretat ion of the study  data.
Prior/Concurrent Clinical Study Experience
8Receipt of any  IMP in the preceding 90 days or expected receipt of IMP during the period 
of study  follow-up, or concurrent participat ion in another intervent ional study  (see 
Table 7).
Other Exclusions
9For wom en only -current ly pregnant (confirmed wit h posi tive pregnancy test) or breast 
feeding.
10Blood drawn in excess of a total of 450 mL (1 unit) for any  reason wi thin [ADDRESS_904780] ions that for legal or ethical reasons bar the enrollment 
of parti cipants who lack capacit y to provi de thei r own informed consent, such subjects are 
excluded.
5.3 Lifesty le Considerations
Parti cipants m ust follow the contraception requirements outlined in Sect ion 5.1.
Restrictions relat ing to concomitant medicat ions are described in Sect ion 6.5.
Agree to wear di gital health device if diagnosed with COVID -19 as described in 
Secti on8.1.5 .
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 36of 1165.3.1 Lifestyle Restrictions
[IP_ADDRESS] Women of Non Childbearing Potential
Women of non -childbearing potential are defined as female participants who are permanent ly 
surgically sterilized or postmenopausal.
Perm anent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral 
salpi[INVESTIGATOR_670042] 6 weeks b efore screening. Bilateral  oophorectomy alo ne is acceptable 
only when the reproductive status of the woman has been confirmed by  [CONTACT_6492]-up horm one 
level assessment.
For wom en aged < 50 y ears, postmenopausal is defined as having both a history  of ≥ 12 
months amenorrhea pri or to randomizat ion, wi thout an al ternat ive cause, fo llowing cessat ion 
of exogenous sex -horm onal treatm ent, and an FSH level in the postmenopausal range. Unt il 
FSH is documented to be within menopausal range, the participant is to be consid ered of 
childbearing potential.
For wom en aged ≥ 50 years, postmenopausal is defined as having a history o f ≥ 12 months 
amenorrhea pri or to randomizat ion, wi thout an al ternat ive cause, fo llowing cessation o f 
exogenous sex -horm onal treatment.
[IP_ADDRESS] Women of Childbearing Potential
A woman is considered of childbearing potential, ie, fertile, fo llowing m enarche and unt il 
beco ming postmenopausal unless permanent ly sterile. W omen of childbearing potential who 
are sexually act ive must agree to use, with their non -sterilized m ale partner, an approved 
method of highly effect ive contraception fro m the time of IMP administration unt il [ADDRESS_904781] hav e received a m edical assessment of surgical success 
(Table5). Women shoul d be stable on thei r chosen method of birth control for at least one 
month befo re dosing.
Highly effective contraception is summarized in Table5. 
Pregnancy Testing
Women of childbearing potential can be included only  after a negat ive urine pregnancy test. 
Urine pregnancy  testing will  be done as per the SoA  (see Sect ion 1.3). If urine tests posit ive or 
indeterminate, a quantitative serum β-hCG will be performed for confirmat ion.
Pregnancy
If the participant beco mes pregnant during the study , this shoul d be reported to the PI. The PI 
[CONTACT_210068] d also be notified of pregnancy  occurring during the study , but confirmed after 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 37of 116completion of the study . The pregnancy  will be followed, and the status of mother and/or child 
will be reported to the Sponsor after delivery .
Apregnancy notificat ion form and fo llow-up will be com pleted. Pregnancy  occurring and 
reported during the study  will be followed up for safet y from the post dose administration to 
end of the study , or un til term , to identify pregnancy outcome, whichever is later. Female 
participants who beco me pregnant after dosing will continue to have all safet y PK (serum  and 
nasal), ADA  serum  sample, and nAb samples collected. These do not represent a safet y risk, 
and serum samples are already  being collected as part of safet y follow-up. Any co mplications 
during the planned fo llow-up of  any pregnant participant (if any ) will be discussed between 
the PI [INVESTIGATOR_255684], and a decisio n to hal t or continue any  further sam pling will be m ade 
on a case by  [CONTACT_413].
Ova Donati on
Female participants should not donate ova for the duration of the study  and f or at l east 
365days after the IMP dose.
[IP_ADDRESS] Male Participants
To avoid transfer of fluids to a sexual partner, all male participants must use a condom starting 
from the time of IM P administration until [ADDRESS_904782] 365 
days after the dose of IMP .
Pregnancy
Parti cipants will be instructed that if their partner becomes pregnant during the study , this 
shoul d be reported to the PI. The PI [INVESTIGATOR_670043] , but confirmed af ter com pletion of  the study . In the event that a participant ’s partner is 
subsequent ly found to be pregnant after the participant is included in the study , then consent 
will be sought fro m the partner and, if granted, any pregnancy  will be followed, and th e status 
of mother and/or child will be reported to the Sponsor after delivery .
A pregnancy notificat ion form and fo llow-up will be com pleted.
5.4 Screen Failures
Screen failures are defined as part icipants who consent to participate in the clinical study  but 
are not subsequent ly rando mly assigned to IMP . A minimal set of screen failure information is 
requi red to ensure transparent reporting of screen failure participants to meet the Consolidated 
Standards of Reporting Trials (CONSOR T) publishing requirements a nd to respond to queries 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 38of 116from regulatory  authori ties. Minimal information includes demography , screen failure details, 
eligibilit y criteria, and any SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
rescr eened if the eligibilit y criterion that resul ted in screen failure has changed in a manner 
that meets eligibilit y. Only  a single rescreening is allowed in the study . Rescreened 
participants shoul d be assigned the same participant number as for the init ial screening. 
Individuals who are rescreened do not need to re -consent for the study .
[ADDRESS_904783] igational interventio n(s), m arketed product(s), or placebo 
intended to be administered to or medical device(s) utilized by a study  parti cipant according to 
the study  protocol .
The thi rd party  medical  device used for assessment of COVID -19 symptoms (i e, digital health 
device [Sect ion 8.1.5 ]) is not considered a study intervent ion.
6.1 IMP(s) Administered
6.1.1 IMP
Parti cipants will be randomized in a 2:1 ratio to receive one single 300 mg dose of AZD7442 
(divided in [ADDRESS_904784] ions, one for each mAb co mponent) or saline place bo (Table 6). 
Invest igational medicinal product will be administ ered on Day 1, and parti cipants will be 
monitored until Day [ADDRESS_904785] ion 7.1.
Table 6 Investigational Pr oducts
Intervention name [CONTACT_99213]7442 (AZD8895 + AZD1061) Placebo (not to be matched to 
AZD7442)
Dose formulation AZD7442 will be supplied as separate 
vials of AZD8895 and AZD1061 as 150 
mg colorless to slightly yellow, clear to 
opalescent solutions for injection. The 
solutions contain 100 mg/mL of active 
ingredient (AZD8895 or AZD1061) in 
20mM L -histidin e/L-histidine 0.9% (w/v) saline 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 39of 116Table 6 Investigational Pr oducts
hydrochloride, 240 mM sucrose, and 
0.04% (w/v) polysorbate 80, at pH 6.0. 
The label -claim volume is 1.5 mL.
Unit dose 
strength(s)300 mg AZD7442 consisting of 150 mg 
AZD8895 and AZD1061 at 100 mg/mL 0.9% (w/v) saline solu tion for 
injection
Dosage level(s) 300 mg single dose of AZD7442
(150 mg of AZD8895 and 150 mg of 
AZD1061)Single dose
Route of 
administration2 IM injections of 1.5 mL each 2 IM injections of 1.5 mL each
Use Experimental Placebo -comparator
Sourcing AZD7442 (AZD8895 + AZD1061): 
[COMPANY_008].0.9% (w/v) saline solution 
supplied by [CONTACT_3885]. 
Packaging and 
labelingIMP will be provided in glass vials. Each 
glass vial will be labeled as required per 
country requirement.Not applicable
IM, intramuscular; IMP, investigational medicinal product; w/v, weight per volume.
6.2 Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all IMP received, and any  discrepancies are reported and 
resolved before use of the IMP.
Only participants enro lled in the study  may receive IMP and only authorized site staff 
may supply  or administer IMP. All IMP must be stored in a secure, environmentally  
contro lled, and monitored (manual or automated) area in accordance with the labelled 
storage condit ions, with access limited to the investigator and authorized site staff.
The invest igator, institution, or the head of the medical inst itution (where applicable) i s 
responsible for IMP accountabilit y, reconciliat ion, and record maintenance (ie, receipt, 
reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused IMPs are provided in 
the Pharmacy Manual or spec ified handling instructions. 
6.2.[ADDRESS_904786] igator and site monitor should be notified immediately .
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 40of 1166.2.1.[ADDRESS_904787] Inspection
AZD7442 IMP is co mprised of 2 separate DPs, AZD8895 and AZD1061, to be administered 
sequent ially. 
Liquid DP
The AZD8895 and AZD1061 DPs are each supplied as sterile, colorless to slightly yellow , 
clear to opal escent, sol utions, wi th a label -claim o f 150 mg at 100 mg/mL  per vial . 
[IP_ADDRESS] Dose Calculation
For AZD7442 (AZD8895 and AZD1061), the doses will be prepared direct ly from the 
AZD8895 and AZD1061 DP vials. AZD8895 and AZD1061 will be administered individually , 
using separate c omponents. 
[IP_ADDRESS] Dose Preparation Steps
The 2 DPs AZD8895 and AZD1061 (comprising AZD7442), must both be administered 
separately  to the parti cipant in sequential order, with no participant receiving doses of 
AZD8895 without also receiving the matching dose of AZD1061. The dose of AZD8895 must 
be administered first. The unblinded IMP Manager or other qualified professio nal shoul d only  
remove the requi red DP vials for participant dosing fro m storage. No inco mpat ibilit ies have 
been observed between AZD7442 and disp osable polypropylene or polycarbonate sy ringes 
used for IM administration.
Dose Preparation and Administration for AZD7442 (AZD8895/AZD1061) 
The dose of AZD7442 (AZD8895 and AZD1061) for administration must be prepared by [CONTACT_1275] ’s or site ’s desi gnated unblinded IMP Manager or other qualified professio nal 
using aseptic technique. T otal time fro m needle puncture of the vial to the start of 
administration must not exceed: 
24 hours at 2 °C to 8 °C (36 °F to 46 °F)
[ADDRESS_904788] be used only once to prepare a single dose. AZD7442 ( AZD8895 and 
AZD1061) does not con tain preservat ives, and any unused portion must be discarded.
Intram uscular AZD7442 doses should be prepared by  [CONTACT_670078] 1.5 mL  volume 
of DP (AZD8895 and AZD1061) into appropriately sized latex -free disposable polypropylene 
or polycarbonate sy ringes. Each DP should be administered sequent ially as separate single 
inject ions, through a [ADDRESS_904789] practice 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 41of 116procedures for IM inject ions, wi th one inject ion in each gluteal region. The IMP does not 
contain preservat ives and any unused portion must be discarded.
Dose Preparation and Administration for Placebo
The dose of placebo (0.9% w/v saline so lution) for administration must be prepared by  [CONTACT_1275] ’s or site ’s designated unblinded IMP Manager or other qualified professio nal 
using aseptic technique. 
Use a separate disposable syringe with a 22 –25 gauge and 1 –1.5 in (25 –38 mm) length 
needle for each placebo inject ion. Each inject ion shoul d be administered as a separate single 
inject ion and administered sequentially . Intram uscul ar doses shoul d be prepared by  [CONTACT_670079] 1.[ADDRESS_904790] be discarded.
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.[ADDRESS_904791] ions for the IR T will be provided to 
each study  site. Randomizat ion will be maintained in a 2:1 ratio within each o f the 2 cohorts:
Cohort 1: Adults ≥ 60 y ears of age, living in lo ng-term care facilit ies. In this context, 
long-term care facilit ies include skilled nursing facilit ies, assisted living facilit ies, and 
independent living facilit ies for senior adults. 
Cohort 2: Other adults ≥[ADDRESS_904792] itutional residences (military 
lodging, dormitori es, etc.), household contacts, healt h care workers, long -term care 
facilit y workers, and workers in occupational or industrial settings in which close contact 
[CONTACT_670080] n. 
Where a participant does not meet all the eligibilit y criteria but incorrectly  received IMP, the 
investigator should inform the Study  Physician immediately , and a discussi on shoul d occur 
between the Study  Physician and the invest igator regarding whether to continue or discontinue 
the participant.
Clinic al Study  Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 42of 1166.3.[ADDRESS_904793] prior to dose preparation (due to 
differences i n container closure), IMP will be handled by [CONTACT_21703] (or 
designee, in accordance with local and institutional regulat ions) at the study  site. Syringe 
masking will be required in order to maintain the blind.
The IR T will provide the invest igator(s) or pharm acists wi th a dose tracking number to be 
allocated to the participant at the dispensing visit. Routines for this will be described in the 
IRT user manual that will be provided to each study site.
The rando mizat ion code should not be broken except in medical emergencies when the 
appropriate management of the participant requires knowledge of the treatment 
rando mizat ion. The investigator documents and reports the action to the Sponsor, without 
revealing the treatment given to the participant t o the Sponsor staff.
The Sponsor retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally  related to the IMP and that potentially require expedited reporting to 
regul atory  authori ties. Rando mization codes will not b e broken for the planned analyses of 
data until all decisio ns on the evaluabilit y of the data from  each individual participant have 
been made and documented.
6.3.[ADDRESS_904794] the immediate management of the 
participant ’s condi tion (eg, anti dote available), the investigator has the sole responsibilit y for 
determining if unblinding of a participants ’ interventi on assignment i s warranted. Participant 
safet y must al ways be the first considerat ion in making such a determinat ion. If a participant ’s 
intervent ion assignment is unblinded, the Sponsor must be notified within [ADDRESS_904795] supervisi on and wi tnessing of the IMP administration. If 
a problem occurs during dosing, such as needle break, no re -dosing is permitted.
6.5 Concomitant Therapy
Permi tted, restri cted, and prohibited medicat ions are summarized in Table7.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 43of 116Any medicat ion or vaccine (including COVID -19 vaccines, over -the-counter or prescript ion 
medicines, vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrollment or receive s during the study  must be recorded, along with:
Reason for use
Dates of administration, including start and end dates
Dosage information, including dose and frequency
The Study  Physician shoul d be contact[CONTACT_670081] t or 
prior therapy .
Table7 Permitted, Restricted, and Pr ohibited Medications
Use Category Type of medication/treatment Timeline/instructions
Permitted Routine Vaccines Licensed influenza vaccines are permitted at any 
time.
All other routine vaccines are permitted beginning 
>30days after IMP dose.
Vaccines for the prevention of SARS -CoV -2 or 
COVID -19 are not considered routine vaccines in 
this protocol, (see Section 5.2).
Allergen immunotherapy Allowed if participant has been receiving stable 
desensitization therapy for allergies at least 30 days 
prior to Visit 1 and there areno anticipated changes
during the treatment period. Allergen 
immunotherapy should not be administered on the 
same day as IMP. Non-prescription over -the-counter 
treatments for allergies such as antihistamines, 
decongestants, and nasal steroids are permitted.
Commercial biologics, prednisone, 
immunosuppressive medications 
(eg, azathioprine, tacrolimus, 
cyclosporine, methotrexate, or 
cytotoxic chemotherapy)Allowed, provided the participant is stable on 
maintenance dose (at steady state) prior to Visit 1.
• Participants may take concomitant medications prescribed by [CONTACT_670082]/or for health maintenance
• Primary  care providers or, where appropriate investigators, should prescribe 
appropriate concomitant medic ations or treatments deemed necessary to provide full 
supportive care and comfort during the study. 
• Participants who develop COVID -[ADDRESS_904796] of care, including investigational agents outside a cli nical trial 
setting. 
Prohibited Not applicable Not applicable
Restricted Contraceptive methods See Section 5.1.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 44of 116Table7 Permitted, Restricted, and Pr ohibited Medications
Use Category Type of medication/treatment Timeline/instructions
Blood/plasma donation Participants must abstain from donating blood or 
plasma from the time of informed consent for one 
year after dose of study drug
COVID -19, coronavirus disease 2019 ; IMP, investigational medicinal product; SARS -CoV-2, severe acute 
respi[INVESTIGATOR_7497] -coronavirus -2.
6.5.1 COVID -19 Vaccine
For prospective participants for STORM CHASER who have not yet been dosed: 
In LTCFs in which an outbreak has been identified, and in whi ch the resi dents have 
not been vaccinated, STORM CHASER could st ill be executed because a vaccine 
will not evoke immunit y fast enough to protect participants in the post -exposure 
setting.
For STORM CHASER participants who have been dosed with investigat ional product, 
when an individual beco mes eligible for the nat ionally  depl oyed COVID -19 vaccine and 
the vaccine is locally  available: 
Parti cipants will be able to be unblinded if they  request thi s, after a fully informed, 
objective discussio n based on all av ailable up -to-date informat ion, and remain in the 
study . 
oUnblinded participants who received placebo should be advised that no 
study -associ ated contraindicat ion to receiving a vaccine exists. 
oUnblinded participants who received AZD7442 should be advised that the 
300mg dose may provide [ADDRESS_904797] ive response to the vaccine might be 
impaired. Such participants should be advised to consider wait ing an appropriate 
length of time (6 to 9 months) before receiving an ant i-SARS-CoV -[ADDRESS_904798] COVID -19 
shoul d be reduced, and after which their potential interference with a vaccine 
may be reduced.
For parti cipants who have received invest igational product (blinded) and develop 
COVID -19, and are sick with it at some point in the study : 
oThere i s no reason to believe that administration of a vaccine during acute 
COVID -19 will ameliorate the illness. 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 45of 116oIn almo st all placebo recipi[INVESTIGATOR_840], and in mos t mAb reci pi[INVESTIGATOR_840], an 
infect ion-induced immune response will occur, and this response should be 
protective. At this time, there is no reason to believe that the protection afforded 
by [CONTACT_670083], so the benefit of vaccinat ion may be limited. 
oThe ri sk of receiving a vaccine after resolut ion of the illness should be low. 
6.[ADDRESS_904799] ion 6.1.1 . Dose modificat ion is not 
permitted. 
6.7 Intervention After the End of the Study
There i s no intervent ion after the end of the study  (see definit ion in Sect ion 4.4).
7 DISCONTINUATION OF I MP AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1 Discontinuation of Study IMP
It may be necessary  for a parti cipant to perm anent ly discont inue (definit ive discon tinuati on) 
IMP. If IMP is permanently discont inued, the participant should remain in the study  to be 
evaluated. See the SoA  (see Section 1.3) for da ta to be collected at the time of discont inuat ion 
of IMP and fo llow-up, and for any  further eval uations that need to be completed.
Note that discontinuation fro m IMP is NOT the same thing as a wit hdrawal fro m the study .
See the SoA  for data to be collected at the time o f intervent ion discontinuation and fo llow-up, 
and for any  further evaluat ions that need to be completed.
7.2 Participant Withdrawal from the Study
A participant may withdraw fro m the study  at any  time at hi s/her own request, or may  be 
withdrawn a t any  time at the di screti on of  the investi gator for safet y, behavioral, 
compliance, or administrative reasons. This is expected to be unco mmo n.
A participant who considers wit hdrawing fro m the study  must be informed by  [CONTACT_122610]-up opti ons (eg, telephone contact, a contact [CONTACT_4490] a 
relative or treating physician, or information fro m medical records).
At the time of withdrawal fro m the study , if possible, an Early Discont inuat ion Visit 
shoul d be conducted, as shown in the SoA (seeSection 1.3). See SoA for data to be 
collected at the time of study  withdrawal and follo w-up, and for any  further evaluat ions 
that need to be compl eted.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 46of 116If the participant withdraws consent for disclosure of future informat ion, the Sponsor may 
retain and cont inue to use any data collected before such a withdrawal o f consent.
If a participant withdraws fro m the study , it shoul d be confirmed if he/she still agrees for 
exist ing samples to be used in line with the original consent. If he/she requests withdrawal 
of consent for use of samples, destruction of any samples taken and not tested should be 
carried out in line with what was stated in the informed consent and local regulat ion. The 
investigator must document the decisio n on use of exist ing samples in the site study  
records and inform the Global Study  Team .
7.[ADDRESS_904800] be taken if a participant fails to return to the clinic for a required 
study  visit:
The study  site must attem pt to contact [CONTACT_4538] r eschedule the missed visit as 
soon as possible, and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to and/or 
shoul d cont inue in the study .
Before a participant is dee med lost to fo llow-up, the invest igator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, 
if necessary , a certified l etter to the parti cipant’s last known mailing address or local 
equivalent m ethods). These contact [CONTACT_13140]’s 
medical record.
Shoul d the participant continue to be unreachable, he/she will be considered to have 
withdrawn from  the study . 
Site personnel, or an independent third party , will  attempt to collect the vital status of the 
participant wi thin legal  and ethical boundaries for all participants randomized, including 
those who di d not receive IMP. Public sources may  be searched for vi tal status 
inform ation. If vital status is determined as deceased, thi s will  be docum ented, and the 
participant will not be considered lost to follow -up. Sponsor personnel will not be 
involved in any attempts to collect vital status info rmation.
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Appendix A.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 47of 1167.4 Study Suspension/Early Termination
The Sponsor reserves the right to temporarily suspend or permanent ly terminate this study  or a 
component of the study  at any  time. The reasons for temporarily suspending the study  may 
include, but are not limited to, the fo llowing:
Any death, SAE, or other safet y finding assessed as related to IMP that, in the opi[INVESTIGATOR_3078] n of 
the Sponsor, may  preclude further administration of IMP.
If one or m ore parti cipant experiences a grade IV hypersensit ivity react ion or 
hypersensit ivity react ion classified as an SAE.
If two or more participants, within the first [ADDRESS_904801] ion.
If two or more participants, within the first [ADDRESS_904802] ion.
In such a situation, no additional part icipants will be randomized or treated with IMP until 
review by  [CONTACT_670084] (see Appendix A5).
If the study  is suspended and does not proceed following evaluat ion of cumulat ive safet y data 
from thefirst [ADDRESS_904803] participant dosed, a 
protocol  amendment will  be submi tted to Heal th Authorities.
8 STUDY ASSESSMENTS AN D PROCEDURES
Study  procedures and their timing are summarized in the SoA. Protocol waivers or
exempt ions are not allowed.
Immediate safet y concerns should be discussed wit h the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
IMP.
Adherence to the study  design requi rements, including t hose specified in the SoA, is 
essent ial and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potential 
participants m eet all eligibilit y criteria. The invest igator will maint ain a screening log to 
record details o f all participants screened and to confirm eligibilit y or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of the ICF m ay be utilized for screening or baseline 
purposes, provided the procedures met the protocol -specified criteria and were performed 
within the t imeframe defined in the SoA.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 48of 1168.[ADDRESS_904804] participa nts weekly (telephone/email/text) through Day [ADDRESS_904805] igator 
will inquire about any  COVID -19 symptoms (see Table8) from the past [ADDRESS_904806] one of the COVID -19 qualifying symptoms lis ted in Table8, the 
participant, hi s/her caretaker, or his/her legal representative must contact [CONTACT_3452]. 
If a participant develops a COVID -19 qu alifying symptom (s) after Day  1, nasopharyngeal 
swabs and anterior nasal swabs will be collected (see Section [IP_ADDRESS] ). If negative, the 
participant w ill be instructed to stop Illness V isits and cont inue with the main scheduled 
assessments (ie, Table 1). If one of these samples is posit ive for SARS -COV -2, the parti cipant, 
his/her caretaker, or his/her legal representative, will be instructed to init iate Illness Visits, and 
the participant will have addit ional assessments per Table2. COVID -19 qualifying 
symptom (s), SARS -CoV-[ADDRESS_904807] results, and/or COVID -[ADDRESS_904808] one of the following symptoms:
Duration Symptom
No minimum durationFever
Shortness of breath
Difficulty breathing
New onset confusion (only for participants ≥60 yo)
Appetite loss or decrease food intake (only for 
participants ≥60 yo)
Increased supplemental oxygen requirement (only for 
participants ≥60 yo on baseline supplemental 
oxygen)
Must be present for ≥2 daysChills
Cough
Fatigue
Muscle aches
Body aches
Headache
New loss of taste
New loss of smell
Clinical Study Pr otocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 49of 116Table8 COVID -[ADDRESS_904809] one of the following symptoms:
Duration Symptom
Sore throat
Congestion
Runny nose
Nausea
Vomiting
Diarrhea
Adapted f rom (CDC 2020 )
CDC, Centers for Disease Control and Prevention; yo, years old 
8.1.2 Severe or Critical Criteria
Severe COVID -19 is characteri zed by  a minimum of either pneumonia (fever, cough, 
tachy pnea, or dy spnea, and l ung infil trates) or hy poxemia (SpO 2< 90% in room air and/or 
severe respi[INVESTIGATOR_36645]) and a WHO Clinical Progression Scale score of 5 or higher .
Table9 WHO Clinical Pr ogression Scale
Patient State Descriptor Score
Uninfected Uninfected, no viral RNA detected 0
Ambulatory mild disease Asymptomatic; viral RNA detected 1
Symptomatic; independent 2
Symptomatic; assistance needed 3
Hospi[INVESTIGATOR_057]: moderate disease Hospi[INVESTIGATOR_057]; no oxygen therapya4
Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_41402]5
Hospi[INVESTIGATOR_057]: Severe Disease Hospi[INVESTIGATOR_057]; oxygen by [CONTACT_670085]6
Intubatio n and mechanical ventilation, 
pO2/FiO2≥150 or SpO 2/FiO2 ≥2007
Mechanical ventilation pO 2/FiO2 < 150 
(SpO 2/FiO2 < 200) or vasopressors 8
Mechanical ventilation pO 2/FiO2 < 150 
and vasopressors, dialysis, or ECMO 9
Dead Death 10
(Marshall et al 2020 )aIf hospi[INVESTIGATOR_198634], record status as for ambulator y patient.
ECMO, extracorporeal membrane oxygenation; FiO 2, fraction of inspi[INVESTIGATOR_1401]; NIV, non -invasive ventilation; 
pO2, partial pressure of ox ygen; SpO 2, oxygen saturation
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 50of 1168.1.3 Illness Visits
Symptom atic parti cipants (as defined in Section 8.1.1 ) will be instructed to visit the study  site 
or to request study  staff to visit their locat ion for init iation of illness assessments ( Table2); 
where supported, home or mobile visits by [CONTACT_670086]. Symptomat ic participants will co mplete the IL -D1 and will be instructed to continue 
with the ho me co llection requirements. Local SARS -CoV-[ADDRESS_904810] ion peri od and p articipants will be informed of their status, which 
shoul d also be reported to the participants ’ primary care providers if applicable. Symptomatic 
participants will cont inue with the Illness Visits until a laboratory result is available. Only 
participants who test positive by [CONTACT_670087] (or central laboratory results, if 
local not available) will be instructed to continue with the illness visit s, including ho me 
collect ion requirements and digital healt h device and Illness e -Diary  recording s. All devices 
and ho me lab kits shoul d be brought to all subsequent illness visits. Parti cipants who test 
negat ive for SARS -CoV-2 will be instructed to stop all illness visit assessments and return the 
digital health device. Parti cipants will cont inue wit h follow-up visit s per Table 1.
The Illness V isit schedule is to be performed in addit ion to the Main Study  Visit  schedule, 
where visits co incide, all as sessments fro m the Main Study  schedule and Illness V isit schedule 
shoul d be perform ed.
To distinguish between the main study ( Table 1) and the Illness Visits (Table2), and to 
distinguish between illness epi[INVESTIGATOR_670044]: f or the first epi[INVESTIGATOR_670045] 1 = 1IL -D1,illness visit Day 3 = 1IL -D3 etc, and for the second epi[INVESTIGATOR_1865] 
2IL-D1, 2IL -D3 and so on as applicable.
8.1.4 SARS -CoV-2 Testing and Other Virology Assessm ents
At the IL -D1, NP swabs will be collected for local and central laboratories and tested for 
SARS -CoV-2 by [CONTACT_670088] R T-PCR assays (see Section [IP_ADDRESS] ).
Resistance monitoring as performed by [CONTACT_670089] o f virus 
isolated from illness visit s may be conducted per the SoA  (see Secti on 1.3andSecti on 
[IP_ADDRESS] ). Addit ionally , a respi [INVESTIGATOR_670046], and as outlined in Sect ion [IP_ADDRESS] .
Anteri or nasal  swabs may  be self -collected during site Illness V isits and by  [CONTACT_6270]-collection at 
home throughout the Illness V isits to quantify duration of viral shed ding (see Section [IP_ADDRESS] ). 
8.1.5 Digital Health Device
At IL-D1, participants will receive a wearable, digital healt h device (eg, Current Health 
Moni toring Sy stem ) and be trained on use of the biosensor . The digital healt h device will 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 51of 116continuously track biophysical parameters, including, but not limited to, serial measurements 
of skin tem perature, heart rate, respi[INVESTIGATOR_2842], bl ood oxy gen saturati on, and physical act ivity.
Data will be obtained fro m the biosensor and transmitted via a wireless hub from the 
participant to the vendor platform. The investigator can monitor participant vital signs and 
receive alerts if there are clinically  significant changes. The data from the device are intended 
to provi de an early indicat ion of worsening healt h status that would allow the invest igator to 
provi de appropri ate fo llow-up. The data are not intended to subst itute for protocol -mandated 
standard safet y monitoring, parti cipant self -reporting, or investigator oversight.
Along with the device, participants will be provided with a paper -based Quick Start Guide 
containing general instructions for the device as well as frequent ly asked questions. A 
reference copy  of the docum ent will be retained in the Site Master File.
8.1.6 Illness e -Diary
An Illness e -Diary  (see Appendix F) will be used to collect self -reported i nform ation about 
COVID -19-associ ated symptom s per di sease cri teria (see Sect ion 8.1.1 ).
At the Day  1 illness visit, participants (or , if applicable, t heir caregiver, surrogate, or legally 
authori zed representative) will be given access to the Illness e -Diary  and trained by  [CONTACT_670090] y of the symptom s.
Parti cipants who test posit ive for SARS -CoV-[ADDRESS_904811] 
negat ive will be instructed to stop Illness e -Diary  recording.
Study  sites will m onitor the heal th status of par ticipants via Illness e -Diary  responses after the 
Day 1 Illness V isit, and will call part icipants as needed based on these responses.
8.2 Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA.
8.2.1 Physical Exa minations
A complete physical examinat ion will be performed at screening fo llowed by [CONTACT_670091]  (see Secti on 1.3).
A co mplete physical examinat ion will include, but not be limited to, assessment of height, 
weight, general  appearance, head, ears, eyes, nose, throat, neck, skin, as well as 
cardi ovascular, respi [INVESTIGATOR_696] , abdo minal, and nervous systems. Each clinically sign ificant 
abnorm al finding at screening will be recorded in the medical history .
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 52of 116A targeted physical examinat ion will  include areas suggested by  [CONTACT_941] m edical  history . Each 
clinically significant abnormal finding fo llowing vaccination will be recorded as an AE .
All physical examinat ions will be performed by a licensed healt hcare provider (eg, phy sician, 
physician assistant, or licensed nurse pract itioner).
8.2.2 Vital Signs
Vital signs, including heart rate, pulse oximetry , blood pressure, and body  temperature, will be 
perform ed as specified in the SoA  (see Secti on 1.3). The participant should be rest ing prior to 
the collect ion of vital signs.
Data collected th rough the digital healt h device on heart rate, respi[INVESTIGATOR_2842], tem perature, 
and oxygen saturation level will be recorded as exploratory  efficacy  measurements and should 
not be reported as AEs, unless they  resul t in an MAAE or SAE.
Situations in which vit al sign resul ts shoul d be reported as AEs are described in Sect ion 8.3.7 .
8.2.3 Electrocardiograms
A triplicate 12 -lead ECGs will be performed at time poin ts specified in the SoA  (see 
Secti on1.3). A 12-lead safety  ECG will be obtained after 5 minutes ’ supi[INVESTIGATOR_198620], using the 
sites own ECG machines.
The PI [INVESTIGATOR_670047]. If abnormal, it wil l be 
docum ented as to whether or not the abnormalit y is clinically  significant by  [CONTACT_978]. For all 
abnorm alities (regardl ess of clinical significance), the specific ty pe and nature of the 
abnorm ality will be docum ented. Clinically significant findings shoul d also be docum ented on 
the AE page of the eCRF , if applicable.
The PI m ay add extra 12 -lead resting ECG safet y assessments if there are any abnormal 
findings or if the PI [INVESTIGATOR_670048] y reason. These assessments 
shoul d be en tered as an unscheduled assessment.
All ECG readings will be digitally stored as source documents.
8.2.4 Clinical Safety Laboratory Assessments
Blood and urine samples for determinat ion of clinical chemistry , hematol ogy, coagul ation, and 
urinalysis will be taken at the visits indicated in the SoA  (see Secti on 1.3).
Addit ional safet y samples may  be collected if clinically indicated, at the discretion of the 
investigator . The date, time of collection, and results (values, units, and reference ranges) will 
be recorded on the appropriate eCRF .
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 53of 116The clinical chemistry , hematol ogy, and urinalysis will be performed at a central laboratory . 
Instructi on for the collec tion and handling of the samples will be provided in the study  
specific Laboratory  Manual.
The fo llowing l aboratory  variables will be measured.
Hematolo gy 
White blood cell (WBC) count Neutrophils absolute count 
Red blood cell (RBC) count Lymphocy tes absolute count 
Hemoglobin (Hb) Monocytes absolute count 
Hematocrit (HCT) Eosinophils absolute count 
Mean corpuscular volume (MCV) Basophils absolute count 
Mean corpuscular hemoglobin (MCH) Platelets
Mean corpuscular hemoglobin concentration 
(MCHC)Reticulocytes absolute count 
Serum Clinical Chemistry
Sodium Alkaline phosphatase (ALP)
Potassium Alanine aminotransferase (ALT)
Urea Aspartate aminotransferase (AST)
Creatinine (and estimated glomerular filtration rate 
[eGFR])Gamma glutamyl transpeptidase (GGT)
Albumin Total Bilirubin
Calcium Conjugated bilirubin
Phosphate Creatine kinase
Glucose
C-reactive protein (CRP)
Urinalysis
Glucose Blood
Protein Microscopy (if positive for protein or blood): 
RBC, WBC, Casts (Cellular, Granular, Hyaline)
Coagulation
International normalized ratio (INR) Prothrombin time (PT)
Activated partial thrombin time (aPTT)
Note: In case a participant shows an AST orALT ≥3×ULN together with total bilirubin ≥2×ULN please refer 
to Appendix D. Actions required in cases of increases in liver biochemistry and evaluation of Hy’s Law, for 
further instructions.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 54of 1168.2.4.[ADDRESS_904812] (women of childbearing potential only)
Serum human beta chorionic gonadotrophin Urine human beta chorionic gonadotrophin (pre -
and post dose)
Pregnancy test (suspected postmenopausal women < 50 years only)
Follicle -stimulating hormone (FSH)
If urine tests positive or indeterminate, a quantitative serum β -hCG will be performed for confirmation.
FSH will be analyzed at the screening visit to confirm postmenopausal status only in women < 50 years 
of age who ha ve been amenorrhoeic for ≥ 12 months. Until FSH is documented to be within menopausal 
range, the participant is to be considered of childbearing potential. For women aged ≥ 50 years, 
postmenopausal is defined as having a history of ≥ [ADDRESS_904813] ion site inspection will be performed according to Table10(see Section 1.3).
Table10 Injection Site Inspection
Proce dure/ Time after both injections have been 
administeredImmediately 
after IMP 
administration30 minutes 
(±10 
minutes)Immediately 
prior to 
participant 
release
Visual inspection of site X X X
Palpatio n of site X X X
Participant will be asked
Are you experiencing any discomfort? X X X
If yes, has the feeling of discomfort 
changed since you received the injectionX X
IMP, investigational medicinal product
Any AEs should be reported as described in Sect ion 8.3.
[IP_ADDRESS] Monitoring After IMP Administration
In addit ion to the injection site inspect ion, safet y monitoring will be performed after IMP 
administration.
The first 15 participants (Sentinel Cohort) will undergo safet y monitoring for [ADDRESS_904814] IMP administration.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 55of 116For the first [ADDRESS_904815] ion.
The definit ions of an AE or SAE can be found in Appendix B.
Adverse events will be reported by  [CONTACT_17071] (or, when appropriate, by  a caregiver, 
surrogate, or the participant ’s legally authori zed representative). 
The invest igator and any designees are responsible for detecting, document ing, and recording 
events that m eet the definit ion of an AE.
8.3.[ADDRESS_904816] igator becomes aware of a SAE with a suspected causal relat ionship to the IMP 
that occurs after the end of the clinical study  in a parti cipant treated by  [CONTACT_198671], the 
investigator shall, wit hout undue delay , report the SAE to the Sponsor .
8.3.2 Follow -up of AEs and SAEs
Any AEs that are unreso lved at the participant ’s last AE assessment in the study are fo llowed 
up by  [CONTACT_83764], but without further recording in the 
eCRF . [COMPANY_008] retains the right to request additional information for any  parti cipant wi th 
ongoing AE(s)/SAE(s) at the end of the study , if judged necessary .
Adverse event variables
The fo llowing variables will be collected for each AE:
AE (verbat im)
The date and time when the AE started and stopped
Severit y grade/maximum severit y grade/changes in severit y grade
Whether the AE is serious or not
Invest igator causalit y rating against the IMP(s) (yes or no)
Action taken with regard to IMP
Clinical Study Protocol –6.0 [COMPANY_008]
AZD74 42–D8850C00003
CONFIDENTIAL AND PROPRIETARY 56of 116If the AE caused partic ipant’s withdrawal fro m the study  (yes or no)
Outcom e
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for SAE
Date invest igator became aware of SAE
AE is seri ous due to
Date of hospi[INVESTIGATOR_059]
Date of discharge
Probable cause of death
Cause of death related to COVID -19 (y es/no/unknown) 
Date of death
Autopsy  performed
Causalit y assessment in relat ion to study  procedure(s)
Causalit y assessment to other medicat ion
The fo llowing severit y ratings will be used, adapt ed fro m the CTCAE v5.0 (NIH 2017 ):
Grade 1: An event of mild intensit y that is usually transi ent and m ay requi re only  clinical  
or diagnostic observations. The e vent does not generally interfere with usual act ivities of 
daily  living. 
Grade 2: An event of moderate intensit y that i s usually  alleviated wi th addi tional, specific 
therapeuti c intervent ion which is minimal, local or non -invasive. The event interferes 
with usual  activi ties of  daily living, causing discomfort, but poses no significant or 
perm anent ri sk of  harm  to the parti cipant.
Grade 3: A severe event that requires intensive therapeutic intervent ion but is not 
immediately  life-threatening. The event inte rrupts usual act ivities o f daily living, or 
significant ly affects the clinical status of the participant. 
Grade 4: An event, and/or its immediate sequelae, that is associated with an imminent risk 
of death and urgent intervention is indicated.
Grade 5: De ath, as result of an event.
It is important to dist inguish between serious and severe AEs:
Severit y is a measure of intensit y, whereas seriousness is defined by  [CONTACT_670092] B2.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 57of 116An AE of severe intensit y need not necessarily be considered serious. For example, 
nausea that persists for several hours m ay be considered severe nausea, but not a SAE. On 
the other hand, a stroke that results in only a limited degree of disabilit y may be 
considered a mild stroke but would be an SAE.
8.3.[ADDRESS_904817] igator should assess causal relationship between IMP and each AE, and answer 
‘yes’ or ‘no’ to the question ‘Do y ou consi der that there is a reasonable possibilit y that the 
event m ay have been caused by  [CONTACT_2203]? ’
For SAEs, causal relat ionship should also be assessed for other medicat ion(s) and study  
procedures. Note that for SAEs that could be associated with any study  procedure the causa l 
relationship is implied as ‘yes’.
A guide to the interpretation of the causalit y question is found in Appendix B.
8.3.[ADDRESS_904818]
AESIs will be co llected according to the time po ints specified in the SoA  (see Secti on 1.3).
AESIs are events of scientific and medical interest , specific to the further understanding of the 
IMP safet y profile, and require close monitoring and rapid co mmunicat ion by [CONTACT_670093] . An AESI can be serious or non -serious. All AESIs will be recorded in the 
eCRF . Seri ous AESIs will b e recorded and reported as per Section 8.3.9 . See also the 
AZD7442 IB, for addit ional information on AESIs.
AESIs for AZD7442 are listed below . They include:
Anaphylaxis and other serious hypersensit ivity reacti ons, including immune complex 
disease (see Appendix E).
Inject ion site reactions.
8.3.5 Med ically Attended Adverse Events
MAAEs will be collected according to the time po ints specified in the SoA  (see Secti on 1.3).
MAAEs are defined as AE s leading to m edically -attended visits that were not routine visits for 
physical examinat ion or vaccinat ion, such as an emergency room visit, or an otherwise 
unscheduled visit to or from medical personnel (medical doctor) for any reason. AEs, 
including abn ormal vital signs, i dentified on a routine study  visit or during the scheduled 
Illness Visits will not be considered MAAEs.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 58of 1168.3.6 Adverse Events Based on Signs and Symptoms
All AEs spontaneously reported by [CONTACT_641614], or reported in respon se to 
the open question from the study  site staff: ‘Have y ou had any heal th probl ems since the 
previous visit/y ou were l ast asked? ’, or revealed by [CONTACT_298334], will be co llected and 
recorded in the eCRF . When co llecting AEs, the recording of diagnoses is preferred (when 
possible) to recording a list of signs and symptoms. However, if a diagnosis is known and 
there are other signs or symptoms that are not generally part of the diagnosis, the diagnosis 
and each sign or symptom will be recorded separately . Symptoms of COVID -19, confirmed 
SARS -CoV-2 infection, and/or diagnosis o f COVID -19 will be collected and recorded in the 
eCRF as an AE.
8.3.7 Adverse Events Based on Examinations and Tests
The results from the protocol -mandated laboratory tests, vital signs, ECG, and other safet y 
assessments will be summarized in the CSR. 
Deteri oration, as com pared to baseline in protocol -mandated safet y assessments, shoul d 
therefore only  be reported as AEs if they fulfill any of the SAE criteria, are the reason for 
discontinuat ion of treatm ent wi th the IMP , or are considered to be clinically relevant as judged 
by [CONTACT_093] (which may include, but not limited to, considerat ion as to whether 
treatm ent or non -planned visits were required or other action was taken with the IMP , eg, dose 
interrupti on).
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported as an AE and the ass ociated l aboratory  resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible, the reporting invest igator 
uses the clinical, rather than the laboratory  term  (eg, anemia versus low hemoglobin value). In 
the absence of clinical signs o r symptoms, clinically relevant deteriorations in non -mandated 
param eters shoul d be reported as AE(s).
Any new or aggravated clinically relevant abnormal medical finding at a physical 
examinat ion, as compared wit h the baseline assessment, will be reported as an AE, unless 
unequivocally related to the DUS.
8.3.8 Hy’s Law
Cases where a participant shows elevations in liver biochemistry  may requi re further 
evaluat ion. Any occurrences of AST or ALT ≥ 3 × ULN, together with TBL  ≥ 2 × ULN and 
confirmed as a HL  case sho uld be reported as an SAE.
AST or ALT ≥ 3 × ULN together with TBL  ≥ 2 × ULN, where no other reason, other than the 
IMP, can be found to explain the co mbinat ion of increases, eg, elevated ALP indicat ing 
cholestasis, viral hepat itis, another drug should be e valuated. The elevat ion in transaminases 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 59of 116must precede or be coincident with (ie, on the same day ) the el evation in TBL, but there is no 
specified t imeframe wit hin which the elevat ions in transaminases and TBL  must occur .
Please refer to Appendix Dfor further instructi on on cases of increases in liver biochemistry  
and evaluat ion of HL.
8.3.[ADDRESS_904819] to be reported, wh ether or not considered causally related to the IMP or to the 
study  procedure(s). All SAEs will be recorded in the eCRF .
If any SAE occurs in the course of the study , investi gators or other site personnel will inform 
the appropriate [COMPANY_008] representat ives within one day , ie, immediately ,but no later  than 
[ADDRESS_904820] igators or other site personnel indicate an AE is seri ous in the EDC system , an 
autom ated em ail alert is sent to the designated [COMPANY_008] representative.
If the EDC system is not available, then the investigator or other study  site staf f reports a SAE 
to the appropriate [COMPANY_008] representative by [CONTACT_756].
The [COMPANY_008] representative will advise the investigator/study site staff how to proceed. 
For further guidance on the definit ion of a SAE, see Appendix B.
The reference document for definit ion of expectedness/listedness is the IB for the [COMPANY_008] 
drug. 
8.3.10 Pregnancy
All pregnancies and outcomes of pregnancy  should be reported to [COMPANY_008], except for:
If the pregnancy  is discovered before the study  parti cipant has received any  IMP.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 60of 1168.3.10.[ADDRESS_904821] iveness of a contraceptive medicat ion. Congenital 
abnorm alities/birth defects and spontaneous miscarriages should be reported and handled as 
SAEs. El ective aborti ons wi thout com plicat ions should not be handled as AEs. The outcome 
of all pregnancies (spontaneous miscarriage, elect ive terminat ion, ectopic pregnancy , normal  
birth, or congenital abnormalit y) shoul d be f ollowed up and docum ented even if the
participant was discont inued fro m the study .
If any pregnancy  occurs in the course of the study , then the investigator or other site personnel 
informs the appropriate [COMPANY_008] representatives within one day , ie, immediately ,but no 
later  than [ADDRESS_904822] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Pati ent Safet y data entry  site within one 
or 5calendar  days for SAEs (see S ection 8.3.9 ) and within 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.
The PREGREP module in the eCRF is used to report the pregnancy and the paper -based 
PREGOUT module is used to report the outcome of the pregnancy .
[IP_ADDRESS] Paternal Exposure 
Male parti cipants shoul d refrain from  fathering a child during the study  and f or 365 day s 
following the dose.
In case of pregnancy o f the partner of a male participant, th e partner ’s pregnancy  should be 
reported on the pregnancy form (consent fro m the partner m ust be obtained before the 
pregnancy form is completed) fo llowing the same timeframe and routing as described for any  
participant ’s pregnancy . Pregnancy of the partic ipant ’s partner is not considered to be an AE. 
These pregnancies will also be fo llowed up, and the outcome of the pregnancy (spontaneous 
miscarri age, el ective terminat ion, ectopic pregnancy , norm al birth, or congeni tal abnorm ality) 
shoul d, if possible, be obtained and documented.
Please refer to Section 8.3.10 for further details.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 61of 1168.3.[ADDRESS_904823] igator to ensure that all 
relevant informat ion is completed wi thin one(Initial Fatal /Life -Threatening or fo llow-up 
Fatal /Life -Threatening) or 5(other serious init ial and fo llow-up) calendar  day(s) if there is 
an SAE associated with the medicat ion error (see Section 8.3.9 ) and within 30 days for all 
other m edicati on errors.
The definit ion of a Medicat ion Error can be found in Appendix B4. 
8.3.12 Device Deficiencies
Any deficiency  observed wi th the di gital heal th device (third -party  medical device) will be 
collected and reported to the ma nufacturer by  [CONTACT_670094], immediately but no l ater than [ADDRESS_904824] ions, use errors, and information supplied by [CONTACT_3455] . The manufacturer ’s 
medical device co mplaint report will be used to collect the deficiency .
8.4 Overdos e
For thi s study , any  dose of AZD7442 > 150 mg of either individual mAb will be considered an 
overdose.
[COMPANY_008] does not recommend a specific treatment for an overdose. Symptoms of overdose 
shoul d be treated as per clinical judgement.
An overdose with associ ated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the eCRF and on the Overdose eCRF module.
An overdose without associated symptoms is only  reported on the Overdose eCRF 
module.
If an overdose on an [COMPANY_008] study dr ug occurs in the course of the study , then the PI [INVESTIGATOR_670049] , but no later  
than 24 hours of when he or she beco mes aware of it.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 62of 116The designated [COMPANY_008] representative works with the PI [INVESTIGATOR_670050] y data entry  site wi thin [ADDRESS_904825] confident iality. For further details on Handling of Human Bio logical 
Samples, see Appendix C.
Samples will  be stored for a m aximum  of 15 y ears fro m the date of the i ssue of the CSR in 
line with consent and local requirements, after which they will be destroyed/repatriated. 
PK samples will be disposed of after the Bioanaly tical Report finalizat ion or 6 m onths 
after issuance of the draft Bioanaly tical Report (whichever is earlier), unless consented 
for future analyses. 
Pharmacokinet ic samples may be disposed of or anonymized by [CONTACT_76435]. Addit ional 
analyses may be conducted on the anonymized, pooled PK sam ples to further 
evaluate and validate the analyt ical method. Any  resul ts from such analyses may be 
reported separately  from the CSR.
Remaining ADA sample aliquots will be retained at [COMPANY_008] or its designee for a 
maximum o f 15 years fo llowing iss ue of the CSR. Addit ional use includes, but is not 
limited to, further characterizat ion of any  ADAs, confi rmation and/or requalificat ion of 
the assay, as well as addit ional assay development work. The results from future analysis 
will not be reported in th e CSR.
8.5.1 Pharmacokinetics Assessments
Serum  samples will be co llected for measurement of serum concentrations of AZD7442 
(AZD8895 and AZD1061), as specified in Table 1and Table2.
Samples may  be collected at addi tional time points during the study  if warranted and agreed 
upon between the investigator and the Sponsor , eg, for safet y reasons. The timing of sampling 
may be altered during the course of the study  based on newly available data (eg, to ob tain data 
closer to the time of peak or trough matrix concentrations) to ensure appropriate monitoring. 
Serumsamples will be used to assess the PK of AZD7442. Samples co llected for analyses of 
AZD7442 serum concentration may  also be used to evaluate safet y or efficacy aspects related 
to concerns arising during or after the study .
Samples will  be collected, l abeled, stored, and shipped, as detailed in the Laboratory  Manual.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 63of 116PK exposure (ie, AUCs) and other PK parameters, if data permit, may be calculated based on 
AZD7442 serum concentrations.
[IP_ADDRESS] Determination of Drug Concentration
Samples for determination of drug c oncentration in serum will be assayed by [CONTACT_670095], using an appropriately validated bioanaly tical 
method. Full details o f the analy tical method used will be described in a separate Bioanaly tical 
Report.
Placebo sam ples will not be analyzed, unless there is a need to confirm that correct treatment 
has been given to study  partici pants. 
Drug concentration informat ion that m ay unblind the study  will not be reported to 
investigat ive sites or blinded personnel un til the study  has been unblinded.
Incurred sample reproducibilit y analysis, if any , will  be perform ed al ongside the bioanalysis 
of the test samples. The results from the evaluat ion, if performed, will be reported in a 
separate Bioanaly tical Report.
8.5.2 Immunogenicity Assessments
Serum  samples for immunogenicit y assessments will be co llected according to Table 1and 
Table2. Sam ples will be co llected, labelled, stored, and shipped as detailed in the Laboratory 
Manual. Results for exploratory  immunogenicit y analyses may  be reported separately  from 
the CS R.
[IP_ADDRESS] Anti -drug Antibody Assessments
Serum  samples for determinat ion of ADA  will be conducted, on behalf of [COMPANY_008], using 
a validated assay . Serum  samples for determination of ADAs will be collected as specified in 
the SoA  (see Secti on 1.3). Unscheduled samples for ADA  analysis should be collected in 
response to suspected immune -related AEs.
The presence or absence of ADA  will be determined in the serum  samples using a validated 
bioanalyt ical method. A tiered testing scheme will be emplo yed, wi th the first step being 
screening. Samples found posit ive in the screening step will be tested in the confirmatory  step. 
Samples confi rmed posi tive for ADA  inthe confirmatory  step will undergo endpoint titer 
determinat ion.
Full details o f the analy tical method and analyses performed will be described in a separate 
Bioanaly tical Report.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 64of 1168.5.2.2 SARS -CoV -2 Serology Assessments
Serum  samples will be co llected to assess S ARS -CoV-2 antigen -specific antibody  levels fro m 
all participants according to the SoA  (see Section 1.3). A rapid point -of-care serology  test will 
beutilized at screening to verify inclusio n criteria. Baseline serostatus and the rate of 
SARS -CoV-2 infection in part icipants receiving AZD7442 versus placebo will be determined 
by [CONTACT_670096] n (negative to posit ive) in a validated SARS -CoV-2 nucleocapsi d assay 
operated by  [CONTACT_670097] . 
[IP_ADDRESS] Assessment of Mucosal Responses
Nasal samples to evaluate PK or SARS -CoV-2 antigen -specific ant ibody  responses in nasal 
secretions will be collected from part icipants according to the SoA  (see Secti on 1.3). Nasal 
adsorpti on specimens will be collected, when test supplies are available, by  [CONTACT_670098] . AZD7442 nasal 
concentrations may be assessed using an appropriately qualified bioanalyt ical assay. 
[IP_ADDRESS] Additional Serum Immunogenicity
Residual serum samples may  be used for expl oratory  immunogenicit y evaluat ion. Serologic 
assessment to seasonal coronavirus antigens may  also be assessed quantitatively using a 
qualified mult iplexed meso scale discovery  (MSD) immunoassay . Expl oratory  sera samples 
may be utilized to investigate addit ional humoral and cellular immune responses, as well as 
potenti al correl ates of protecti on as determined by [CONTACT_670099] , 
efficacy , and immunogenicit ydata.
8.5.3 Pharmacodynamics
[IP_ADDRESS] SARS -CoV -2 Neutralizing Antibody Assessments
Serum  samples to m easure SARS -CoV-2 nAb l evels will  be collected from  parti cipants 
according to the time po ints specified in the SoA  (see Secti on 1.3). Authorized laboratories 
may measure neutralizing ant ibodies to SARS -CoV-2 using validated wild -type neutralizat ion 
assay or pseudo -neutralizat ion assays.
8.6 Human  Biological Sample for B iomarkers
8.6.1 Collection of mandatory samples for biomarker analysis
By [CONTACT_670100] , the parti cipant consents to the mandatory  research 
components of the study . 
Samples for bi omarker research are required and will be co llected fro m participants, as 
specified in the SoAs (see Sect ion 1.3). Nasopharyngeal swabs will be collected for viro logic 
assessments. Anteri or nasal  swabs ma y be co llected at site Illness V isits and by [CONTACT_670101]-collection peri od. These bio marker m easurements will support 
understanding of potential correlates of protection, duration of immune responses, and 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 65of 116correl ations between pharmacod ynamics and immunogenicit y. Details for sam ple collect ion, 
processing, and testing will be provided in the Laboratory  Manual .
Any results fro m such analyses may be reported separately fro m the CSR.
[IP_ADDRESS] Virologic Assessments
Instructi ons for obtaining and proce ssing NP swab samples are provided in the Laboratory 
Manual. NP swabs will be assessed by [CONTACT_113640] R T-PCR assays for the detection of 
SARS -CoV-2 by [CONTACT_670102]. Further details will be provided in the 
Virology Analysis plan.
Addit ionally, a validated m ultiplexed respi [INVESTIGATOR_670051] a central laboratory  operated on behalf 
of the Sponsor .
[IP_ADDRESS] Assessment of Viral Shedding
Viral shedding m ay be assessed in self-collected anterior nasal swabs co llected at site Illness 
Visits or self -collected at home, by [CONTACT_15322] R T-PCR assay for the qualitat ive and/or 
quant itative measurement of SARS -CoV-2 in participants whose medical condit ion allows. 
8.6.2 Other Study -related Biomarker Research
Already co llected samples may be analyzed for different bio markers thought to play a role in 
COVID -19 severit y or outcom es, including, but not limited to, serum, plasma or mucosal 
cytokines, quant ificat ion of RNA, micro -RNA, and/or non-coding RNA, using quant itative 
RT-PCR, microarray , sequencing, or other technology  in blood, or mucosal specimens to 
evaluate their associat ion with observed clinical responses to AZD7442. Other study -related 
biomarker research excludes genetic analysi s.
For storage, re -use, and destruction of bio marker samples see Section 8.5. 
8.[ADDRESS_904826] ion 
in the control group. The null hypothesis is: Efficacy  of AZD7442 compared to placebo in 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 66of 116prevent ing COVID -19 is equal to zero. Whereas, the alternative hypothesis is: Efficacy o f 
AZD7442 compared to placebo in preventing COVID -19 is not equal  to zero. That i s:
Null hypothesis: Efficacy = 0
Alternat ive hypothesis: Efficacy ≠ [ADDRESS_904827] ical 
significance will be achieved if the 95% CI lower bound is > 0.
9.2 Sample Size Determination
Up to 1 125 participants will be rando mized in a 2:1 ratio to receive a single IM dose of 
AZD7442 (divi ded in 2 sequent ial injecti ons, one for each mAb component) (the active group, 
n = approximately 750) or saline placebo (the control group, n = approximately 375) on 
Day 1.
The sample size calculat ions are based on the primary  efficacy endpo int and were d erived 
following a m odified Poisson regressio n approach (Zou 2004 ). All part icipants will be 
followed for the entire durati on of  the study . The primary  analysis will be conducted [ADDRESS_904828] approximately  90% 
power to demonstrate that the lower bound of the 2 -sided 95% CI for efficacy is greater t han 
zero, assuming an attack rate of 4.5% in the placebo group and true efficacy o f 75% (equating 
to an attack rate of 1.1% in the AZD7224 group). 
To mitigate the uncertaint y around these assumpt ions, a BSSR may be conducted prior to the 
primary  analysis. The overall event rate, as well as the data from external sources (eg, 
prophylact ic efficacy o f other COVID -19 preventive mAbs), will be used in the sample size 
re-estimat ion and strict ly no treatm ent inform ation fro m this study  will be used in the review . 
The summaries will not contain any information that would potentially reveal treatment 
assignments. The review may result in an adjust ment of sample size when the observed attack 
rate is lower than expected. Since this review will be performed in a blind ed fashi on, no 
adjustm ent for the T ype I error i s needed. Full details will be in a BSSR plan.
9.3 Populations for Analyses
The fo llowing popul ations are defined:
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 67of 116Table 11 Populations for  Analysis
Population/Analysis set Description
All participants analysis set All participants screened for the study, to be used for reporting disposition 
and screening failures.
Full analysis set All randomized participants who received at least one dose of IMP, 
irrespective of their protocol adherence and continued participation in the 
study. Participants will be analyzed according to their randomized treatment 
irrespective of whether or not they have prematurely discontinued, 
according to the intent -to-treat principle. Participants who withdraw consen t 
or assent to participate in the study will be included up to the date of their 
study termination.
Safety analysis set The safety analysis set consists of all participants who have received at least
one dose of IMP. Erroneously -treated participants (eg, those randomized to 
treatment A, but were actually given treatment B) are accounted for in this 
analy sis set by [CONTACT_198678]. A 
participant w ho has o n one or several occasions received active IMP is 
classified as active. 
Pharmacokinetic analysis set All participants who received AZD7442 and from whom PK blood samples 
are assumed not to be affected by [CONTACT_670103] e quantifiable serum PK observation post dose will be 
included in the PK analysis dataset.
IMP, investigational medicinal product; PK, pharmacokinetic
9.[ADDRESS_904829] been observed 
across the active and control groups (see Section [IP_ADDRESS] ). Thedate for the DCO for th is 
analysis will be calculated as date of onsetof primary  endpoint event (+30 days). All data 
collected during this interval includ ingadditionalprimary  endpoints events will be evaluated. 
All participants in the study  will be assessed for efficacy with all data available through their 
last assessment up to visit Day  366and PK, ADA, nAbs and safet y will be assessed up to [ADDRESS_904830] important endpoints, including 
primary  and key  secondary  endpoints.
The study  will initially be com pletely double -blind until the primary  analysis (i e, blind for 
participants, invest igators/site staff, and Sponsor/designated cl inical  research organizat ion) at 
which time members of Sponsor/designated clinical research organization associated with the 
analysis, write -up and submissio n will be unblinded. T o maintain the integrit y of the study  to 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 68of 116allow rigorous evaluat ion of efficac y and safet y through the end of the study , the si te 
personnel and participants will remain blinded to the treatment assignment until the end of the 
study . The primary  analysis will be carried out by  [CONTACT_670104] 
(or its del egates) and the procedure will be detailed in an unblinding plan. Participant -level 
unblinding informat ion will be kept strict ly confident ial and rati onale for any  unblinding will 
be docum ented. 
Categorical variables will be summarized using frequency and per centages, where the 
deno minator for calculat ion is the underlying analysis set populat ion, unless otherwise stated.
Continuous variables will be summarized wit h descri ptive statist ics of number of available 
observat ions, m ean, standard deviat ion, median, m inimum and maximum, and quartiles where 
more appropri ate.
All po int estimates will be presented with a 95% CI, unless otherwise stated. P -values, 
corresponding to a [ADDRESS_904831] ion 9.4.5 .
9.4.1 General Considerations
The primary  efficacy analysis will be based on the double -blind, placebo -controlled -phase of 
the study , and will co mpare participants rando mized to receive a single IM dose of AZD7442 
(×2 IM injections) against participants randomized to saline placebo. 
The primary  estimand will  be used for the analysis of the primary  efficacy  endpoint. It will be 
based on participants in the full analysis set, defined as all rando mized participants who 
received at least one dose of IMP , analyzed according to their rando mized treatment. For 
participants wi th multiple events, only  the first occurrence will be used for the primary 
efficacy endpo int analysis. The set of intercurrent events for this est imand consists of 
participants who beco me unblinded to properly consider va ccinat ion for COVID -19, take a 
COVID -[ADDRESS_904832] prior to having met the primary 
efficacy endpo int. The intercurrent events will be handled using the treatment policy strategy . 
Absence of data fo llowing parti cipants ’ withdrawal prior to having met the primary  efficacy  
endpo int will be treated as missing. Participants will be considered as not having the event 
through the time o f last observat ion. Deaths that are caused by [CONTACT_4113] -19 and 
hospi [INVESTIGATOR_670052] -19 (Section 8.1.2 ) will also be 
considered as primary  efficacy  endpoints. 
Addit ional estimands will be specified for the primar y efficacy endpo int to carry  out 
sensit ivity analyses for assessing the robustness of results. These sensit ivity analyses will 
explore different methods for handling intercurrent events and different assumpt ions for 
missing data. Estimands will also be spe cified for the analysis o f secondary endpo ints. Full 
details will be provided in the SAP .
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 69of 116Dem ography  and baseline characterist ics will be summarized by [CONTACT_670105]. If there are major differences between the full analysis set and th e safet y analysis set, the 
summaries will be repeated and presented for the safet y analysis set.
9.4.2 Efficacy 
[IP_ADDRESS] Primary Endpoint
The primary  endpoint is the first case of SARS -CoV-[ADDRESS_904833] R T-PCR -confi rmed SARS -CoV-2 prior to Day  183 and meet the 
qualifying symptoms summarized in Table8. If a participant ’s first case of SARS -CoV-[ADDRESS_904834] parti cipant, regardl ess of 
the number of events. This analysis will not be controlled for mult iplicity and statistical 
hypotheses will be tested at a nominal 5% significance level (based on a [ADDRESS_904835]) . 
As the primary  efficacy analysis, the plan is to use the primary est imand and a Poisson 
regression model with robust variance (Zou 2004 )to analyze the primary  efficacy  endpoint, 
which will include the log of the fo llow-up time as an offset. If a participant ’s first case of 
SARS -CoV-2 RT-PCR posit ive symptomatic illness occurs after Day 183, the participant will 
be considered as not having an event. The efficacy will be estimated from the model, which 
will give the RRR in the incidence o f SARS -CoV-2 RT-PCR -positivesymptom atic illness. 
The efficacy is calculated as RRR = 100% × (1 -relative risk), which is the incidence of 
infect ion in the AZD7442 group relative to the incidence of infect ion in the control group, 
expressed as a percentage. Model assumpt ions will be c hecked and the robustness of the 
primary  analysis will be assessed. The Poisson regressio n model with robust vari ance has the 
flexibilit y for expl oring m ultiple imputati on approaches using, eg, the observed placebo attack 
rate to impute missing data. If th e Poi sson regression model wit h robust variance fails to 
converge, an alternat ive approach will be implemented. Full details will be documented in the 
SAP.
At the final analysis, the efficacy will also be est imated fro m a Poi sson regressio n model with 
robust variance and o ffset including the log of the fo llow up time, which includes all 
SARS -CoV-[ADDRESS_904836] dose of IMP and prior to Day  183. In addi tion, the absol ute ri sk reducti on of  
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 70of 116AZD7442 over placebo in prevent ing the incidence of the SARS -CoV-2 RT-PCR posit ive 
symptom atic illness will be presented, along with the 2 -sided 95% CI using the Miettinen and 
Nurminen ’s score m ethod (Miettinen and Nurminen 1985 ). Full details will be documented in 
the SAP .
[IP_ADDRESS] Secondary Endpoint(s)
The key  secondary  endpoint is the incidence of the first case of SARS -CoV-2 RT PCR -
positive and severe or critical symptomat ic illness that occurs prior to Day 183. The criteria 
for determining this endpo int is the same as those for the primary  efficacy  endpoint (see 
Secti on9.4.2.1 ).Details on mult iplicity control are provided in Sect ion 9.4.5 .
Other secondary  endpoints include the fo llowing summary  measures, derived from binary  
outcom es:
The incidence of participants who have a post -treatment response (negat ive at baseline to 
positive at any  time post -baseline) for SARS -CoV -2 nucleocapsid ant ibodies. 
The incidence of COVID -19-related death occurring after dosing with IMP.
The incidence of all-cause m ortali ty occurring after dosing wit h IMP.
Following the sam e methodol ogy outlined for the primary  endpoint, each of these secondary  
endpo ints will be analyzed by a separate Poisson regressio n model with robust variance (Zou 
2004 ). RRR will be est imated from each model, with a corresponding 95% CI. A p-value, 
corresponding to a [ADDRESS_904837] placebo. The 
key secondary  efficacy  endpoint (whose alpha is protected under a hierarchical framework) 
will be presented with 95% CIs and p -values for other secondary endpo ints will be no minal, 
as they  are not controlled f or multiplicity. To support these analyses, descript ivestatistics will 
be produced for the AZD7442 and control groups. Full details will be documented in the SAP .
[IP_ADDRESS] Exploratory Endpoint(s)
Full details o f the analyses for the exploratory  endpoints will be s pecified in the SAP .
9.4.3 Safety
[IP_ADDRESS] Primary Endpoint(s)
The safet y of AZD7442 will primarily be assessed by:
Incidence of AEs 
Incidence of SAEs 
Incidence of MAAEs 
Incidence of AESIs 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 71of 116AE severit y will be graded according to Appendix Band coded using the most recent version 
of the Medi cal Dict ionary for Regulatory  Activities. AEs will be presented for each treatment 
group by  [CONTACT_103467]. Summaries will include the number and 
percentage of participants reporting at least one event, number of events, and exposure 
adjusted rates, where appropriate.
An overview of AEs will be presented for each treatment group, including t he number and 
percentage of participants with any AE and SAEs. Summaries will present the relat ionship to 
IMP as assessed by [CONTACT_3170] , maximum intensit y, seriousness, and death.
A listing will cover details for each individual AE. Full details o f all AE analyses will be 
provi ded in the SAP .
[IP_ADDRESS] Other Safety Endpoint(s)
Laboratory  parameters (hem atology, clinical chemistry , coagul ation, and urinalysis)
12-lead safet y ECG
Vital signs (blood pressure, pulse rate, oral temperature, and respi[INVESTIGATOR_2842])
Physical examinat ion
Laboratory  assessments will be performed for hematology , clinical chemistry , coagulati on, 
and urinalysis parameters. Laboratory  parameters will be graded using the most recent version 
of the CTCAE. 
Addit ionally , per the SoA  (see Secti on1.3), all participants will be evaluated via ECG, vital 
signs, and a targeted phy sical examinat ion. All parameters from laboratory , ECG, vi tal signs, 
and physical examinat ion assessments will be summarized with descript ive statist ics based on 
data ty pe (continuous, categorical, etc.). No hy pothesis testing or CIs will be performed or 
calculated, unless otherwise specified. Full details of safet y endp oints analysis will be 
provi ded in the SAP .
9.4.4 Pharmacokinetic and Anti -drug Antibody
[IP_ADDRESS] Pharmacokinetic
Individual AZD7442 (AZD8895 and AZD1061) serum  concentrati on data will be listed and 
tabul ated by  [CONTACT_3227], al ong wi th descri ptive statist ics. Pharmac okinet ic exposure (ie, 
AUCs) and other PK parameters may be est imated using non -compart mental analysis, if data 
permit. Potential correlat ion between PK exposure and efficacy/safet y response may  be 
explored. Populat ion PK analysis may be performed and repo rted in a separate report.
[IP_ADDRESS] Anti -drug Antibody
The incidence of ADA  to AZD7442 will be assessed and summarized by [CONTACT_670106]. The ADA  titer will  be 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 72of 116listed by  [CONTACT_670107]. The impact of ADA  on PK, PD, efficacy , and 
associ ation with AEs and SAEs, will be assessed. 
9.4.[ADDRESS_904838] of subgroups includes but may not be limit ed to: age, sex, race, ethnicit y, com orbidi ty, and 
SARS -CoV-[ADDRESS_904839] as soon as 
practi cal after randomization of the study ’s 100thparticipant or after [ADDRESS_904840]. Study  enrollment will not be paused pending or 
during thi s evaluat ion by [CONTACT_4318]. 
For details on the DSMB, refer to Appendix A5. Further details, composit ion, and operation 
of the independent DSMB will be described in a DSMB Charter .
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 73of [ZIP_CODE] SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 74of 116Appendix ARegulatory, Ethical, and Study Oversight Considerations
A1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidel ines, including the 
Declaration of Helsinki and Council for International Organizat ions of Medical 
Sciences (CIOMS) International Ethical Guidelines
Applicable ICH GCP Guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, IB, a nd other relevant documents (eg, 
advert isements) must be submitted to an IRB/IEC by [CONTACT_133419]/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC and applicable Regulatory  
Authori ty approval  before implementati on of  changes m ade to the study  design, except 
for changes necessary  to eliminate an immediate hazard to study  parti cipants.
[COMPANY_008] will be responsible for obtaining the required authorizat ions to conduct the 
study from the concerned Regulatory  Authori ty. This responsibilit y may be delegated to a 
CRO, but the accountabilit y remains wi th [COMPANY_008].
The invest igator will be responsible for providing oversight of the conduct of the study at 
the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, 
European Regulation 536/2014 for clinical studies (if applicable), European Medical 
Device Regulation 2017/745 for clinical device research (if applicable), and all other 
applicable local regulat ions.
Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_261760] a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies toward the safet y of parti cipants and the safet y of 
the IMP under clinical invest igation are m et.
The Sponsor has a legal responsibilit y to notify  both the l ocal Regulatory  Authori ty and 
other regulatory  agencies about the safet y of the IMP under clinical invest igation. The 
Sponsor will co mply with country -specific regulatory  requi reme nts relating to safet y 
reporting to the regulatory  authori ty, IRB/IEC, and invest igators.
For all studies, except those utilizing medical devices, invest igator safet y reports m ust be 
prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) accor ding to local 
regul atory  requi rements and Sponsor policy, and forwarded to invest igators as necessary.
European Medical Device Regulat ion 2017/745 for clinical device research (if 
applicable), and all other applicable local regulat ions
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 75of 116An invest igator who receives an invest igator safety report describing a SAE or other 
specific safet y informat ion (eg, summary or list ing of SAEs) fro m the Sponsor will 
review and then file it along wit h the Invest igator’s Brochure and will notify the IRB/IEC, 
if appropriate a ccording to local requirements.
A2 Financial Disclosure
Invest igators and sub -invest igators will provide the Sponsor with sufficient, accurate financial 
inform ation, as requested, to allow the Sponsor to submit co mplete and accurate financial 
certification o r disclosure statem ents to the appropri ate regul atory  authori ties. Investi gators 
are responsible for providing information on financial interests during the course of the study 
and for one y ear af ter com pletion of the study .
A3 Informed Consent Process
The in vestigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authori zed representative and answer all quest ions regarding 
the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary, and they are f ree to 
refuse to participate and may wit hdraw their consent at any  time and for any  reason during 
the study . Partici pants or thei r legally  authori zed representative will be required to sign a 
statement of informed consent that meets the requirem ents of [ADDRESS_904841] (HIPAA) 
requi rements, where applicable, and the IRB/IEC or study  center.
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was 
obtained. The authorized person obtaining the info rmed consent must also sign the ICF.
Parti cipants m ust be re -consented to the most current versio n of the ICF( s) during their 
participat ion in the study.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  
authori zed representative.
A participant who i s rescreened is not required to sign another ICF .
The ICF will contain a separa te secti on that addresses and documents the collect ion and use of 
any mandatory  and/or opti onal human bio logical  sam ples. The invest igator or authorized 
designee will explain to each participant the objectives of the analysis to be done on the 
samples and any potenti al future use.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 76of 116Parti cipants will be tol d that they  are f ree to refuse to participate in any  optional samples or 
the future use and may wit hdraw their consent at any t ime and for any reason during the 
retenti on peri od.
A4 Data Protection
Parti cipants will be assigned a unique ident ifier by [CONTACT_1034] . Any part icipant records or 
datasets that are transferred to the Sponsor will contain the ident ifier only; part icipant names 
or any  informat ion that would make the participant identifiable will not be t ransferred.
The parti cipant m ust be inform ed that hi s/her personal  study -related data will  be used by  
[CONTACT_9324]. The level of disclo sure and use 
of their data m ust al so be explained to the participant in the i nformed consent. 
The parti cipant m ust be inform ed that hi s/her m edical  records m ay be examined by 
[CONTACT_17080] y Assurance auditors or other authorized personnel appo inted by  [CONTACT_429], by  [CONTACT_17081]/IEC m embers, and by  [CONTACT_670108].
A5 Committees Structure
The safet y of all Sponsor clinical studies is closely monitored on an ongoing basis by [CONTACT_325410] y. Issues ident ified will be addressed; for 
instance, this could invo lve am endments to the CSP and letters to investigators.
Data and Safety Monitoring Board (DSMB)
An external DSMB will monitor and protect the safet y of the parti cipants throughout the 
doubl e-blind treatment period of the study . The DSMB members will be selected for thei r 
expert ise. The voting members of the DSMB will be co mprised of external individuals 
including the DSMB chair . Summaries of unblinded data will be prepared and provided to the 
DSMB. T o minimize the potential introduction of bias, DSMB members will not have direct 
contact [CONTACT_670109]. The data for review will be outlined in 
the DSMB charter and will be agreed to in advance by  [CONTACT_87110]. Data Review 
Meet ings will be held monthly unt il last parti cipant l ast vis it to revi ew data rel ating to 
participant safet y and qualit y of study  conduct.
The DSMB will review safet y data on a regular basis as set out in the DSMB charter, 
including, but not limited to, reviewing cumulat ive safet y data from  the first [ADDRESS_904842] as soon as practical after rando mizat ion of the study ’s 
100th participant or after [ADDRESS_904843]. Study 
enrollment will not be paused pending or during this evaluat ion by  [CONTACT_4318]. After 
completing this review , the DSMB will specifically  advise the Sponsor on whether it is 
appropriate to continue the study . During any subsequent safet y reviews by  [CONTACT_4318], 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 77of 116participant enrollment can continue. The available unblinded s afety data for the randomized 
participants will be evaluated by  [CONTACT_4318]. Safety  and efficacy summaries will be prepared 
prior to each m eeting. The efficacy summaries will be presented for safet y review purposes. 
During the study , the benefit/risk assessme nt will be continuously mo nitored by  [CONTACT_670110]. Specifically , the study  may be paused for DSMB 
review if a statist ically significantly higher risk ratio (> 1), at the 1 -sided 5% si gnificance 
level, i s seen for ca ses of severe COVID -[ADDRESS_904844] accrued in the study  and will occur during each monthly  DSMB data revi ew 
or soone r if there are 5 or more severe cases accrued compared to the previous assessment. 
Based on the output of the review , the study  coul d be paused for further evaluat ion of the 
potenti al signal . 
The DSMB can recommend modificat ions of the protocol to enhance partici pant safet y and to 
recommend early terminat ion of the study  if there is strong evidence that AZD7442 or 
continuat ion of the study  poses a safet y concern to participants.
A6 Dissemination of Clinical Study Data
A descri ption of this clinical study  will be available on 
http://astrazenecagrouptrials.pharmacm.com and http://www .clinicaltrials.gov as will the 
summary of the study  resul ts when they  are available. The clinical study  and/or summary of 
study  resul ts may  also be available on other websit es accor ding to the regulations of the 
countri es in which the study  is conducted.
A7 Data Quality Assurance
All participant data relat ing to the study  will be recorded in the eCRF, unless transmitted 
to the Sponsor or designee electronically (eg, laboratory  data). Th e invest igator is 
responsible for verifying that data entries are accurate and correct by  [CONTACT_122642].
The invest igator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons, and provi de di rect access to source data documents.
Moni toring details describing strategy  (eg, risk -based init iatives in operations and qualit y, 
such as Ri sk Management and Mit igation Strategies and Analyt ical Risk-Based 
Moni toring), m ethods, responsibilit ies and requirements, including handling of 
nonco mpliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in the rel evant study  plans.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD 7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 78of 116The Sponsor or designee is responsible for the data management of this study  including, 
qualit y checking of the data.
The Sponsor assumes accountabilit y for acti ons delegated to other individuals (eg, 
CROs).
Study  monitors will perform  ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_1191], complete, and verifiable fro m 
source documents; that the safet y and ri ghts of  participants are being protected; and that 
the study  is being conducted in accordance with the currently approved protocol and any 
other study  agreem ents, ICH GCP, and all applicable regulatory  requi rements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained by t he invest igator for [ADDRESS_904845] itutional policies requi re a l onger retenti on peri od. No records m ay be 
destroy ed during the retention period without the written approval of the Sponsor. No 
records m ay be transferred to another location or party  without wri tten notificat ion to the 
Sponsor.
A8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of the data collected. Source documents are file d at the invest igator’s site.
Data entered in the eCRF that are transcribed from source documents must be consistent 
with the source documents or the discrepancies must be explained. The investigator may  
need to request previous medical records or transfer records, depending on the study. 
Also, current medical records must be available.
Definit ion of what constitutes source data can be found in the study  monitoring plan. 
A9 Study and Site Start and Closure
The first act of recruitment is the first participan t screened and will be the study  start date. The 
Sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the Sponsor . Study  sites will be cl osed upon study  
completion. A study  site is considered cl osed when all  requi red docum ents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by [CONTACT_18484] i nvest igator may include, but 
are not limit ed to:
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 79of 116Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/I EC 
or local health authori ties, the Sponsor's procedures, or GCP guidelines
Inadequate recruit ment of parti cipants by  [CONTACT_17062]
Discontinuati on of  further IMP development
If the study  is prem aturely  terminated or suspended, the Sponsor shall prompt ly inform the 
investigators, the IECs/IRBs, the regulatory  authorit ies, and any CRO(s) used in the study  of 
the reason for terminat ion or suspensio n, as specified by [CONTACT_271127]. The invest igator shall prompt ly inform the parti cipant and shoul d assure 
appropriate participant therapy  and/or foll ow-up.
Parti cipants from  terminated si tes will  have the opportuni ty to be transferred to another site to 
continue the study .
A10 Publication Policy
The results of this study  may be published or presented at scient ific meet ings. If this is 
foreseen, the invest igator agrees to submit all manuscripts or abstracts to the Sponsor 
before submissio n. This allows the Sponsor to protect proprietary  information and to 
provi de comments.
The Sponsor will comply with the requi rements for publicat ion of study  resul ts. In 
accordance with standard editorial and ethical practice, the Sponsor will generally support 
publicat ion of mult i-center studi es only  in thei r entirety  and not as individual site data. In 
this case, a co -ordinat ing invest igator will be designated by [CONTACT_11402].
Authorship will be determined by  [CONTACT_73008] h Internat ional 
Committee of Medical Journal Editors authorship requirements.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 80of 116Appendix BAdverse Events: Definitions and Pr ocedures for Recording, 
Evaluating, Follow -up, and Reporting
B1 Definition of Adverse Events
An AE is the development of any untoward medical occurrence in a patient or clinical study 
participant administered an IMP and which does not necessarily have a causa l relationship 
with this treatm ent. An AE can therefore be any unfavorable and unintended sign (eg, an 
abnorm al laboratory  finding), symptom (eg, nausea, chest pain), or disease temporally  
associ ated wi th the use of an IMP , whether or not considered relate d to the IMP . 
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre -exist ing medical occurrence. An AE may occur at any  time, including 
run-in or washout periods, even if no IMP has been administered.
B2 Definition of Serious Adverse Events
A SAE is an AE occurring during any study phase (ie, run -in, treatment, washout, fo llow-up), 
that fulfills one or more of the fo llowing criteria:
Results in death
Is immediately life -threatening
Requi res in -partici pant hos pi[INVESTIGATOR_325352] 
Results in persistent or significant disabilit y or incapaci ty 
Is a congenital abnormalit y or birth defect
Is an important medical event that may jeopardize the participant or may require medical 
treatment to prevent one of the outcomes listed above
Adverse events for malignant tumors reported during a study  shoul d generally be assessed as 
SAEs . If no other seriousness criteria apply , the ‘Important Medi cal Event ’ criterion shoul d be 
used. In certain situations, however, medical judgement on an individual event basis should be 
applied to clarify that the malignant tumor event should be assessed and reported as a non-
serious AE. For exam ple,if the tumor is included as medical history and progression occurs 
during the study , but the progression does not change treatment and/or prognosis of the 
malignant tumor, the AE m ay not fulfills the attributes for being assessed as serious, although 
reporting of the progression of the malignant tumor as an AE is valid and should occur .Also, 
some ty pes of  malignant tum ors, which do not spread remotely after a routine treatment that 
does not require hospi[INVESTIGATOR_3094], may be assessed as non -serious; examples in adult s include 
Stage 1 basal cell carcino ma and Stage 1A1 cervical cancer removed via cone biopsy .
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 81of 116Life-threatening
‘Life-threatening ’ means that the participant was at immediate risk of death fro m the AE as i t 
occurred or it is suspected that use or c ontinued use of the IMP would result in the 
participant ’s death. ‘Life-threatening ’ does not m ean that, had an AE occurred in a more 
severe form, it might have caused death (eg, hepatitis that resolved without hepatic failure).
Hospi[INVESTIGATOR_670053] a SAE, although the reasons for it 
may be (eg, bronchospasm, laryngeal edema). Hospi[INVESTIGATOR_33094]/or surgical operations 
planned before or during a study  are not consi dered AEs if the illness or disease e xisted before 
the participant was enro lled in the study , provi ded that i t did not deteriorate in an unexpected 
way during the study .
Important Medical Event or Medical Treatment
Medical and scientific judgement should be exercised in deciding whether a cas e is seri ous in 
situations where important m edical events may  not be immediately life -threatening or resul t in 
death, hospi [INVESTIGATOR_3094], disabilit y or incapaci ty but may jeopardize the parti cipant or m ay 
requi re medical treatm ent to prevent one or more outco mes listed in the definit ion of seri ous. 
These should usually be considered as serious.
Simply stoppi[INVESTIGATOR_33095]; medical 
judgement must be used.
Angioedema not severe enough to require intubation but requiring IV hydrocortisone 
treatm ent
Hepatotoxicit y caused by [CONTACT_33153] l (acetaminophen) overdose requiring treatment with 
N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias (eg, neutropenia or anemia requiring blood transfusio n, etc) or 
convulsio ns that do not result in hospi[INVESTIGATOR_3094]
Development of drug dependency or drug abuse
Severity Rating Scale (adapted from CTCAE v5.0):
Grade 1: An event of mild intensit y that is usually transi ent and m ay requi re only  clinical  
or diagnostic observations. The event does not generally  interfere wi th usual  activi ties of  
daily  living.
Grade 2: An event of moderate intensit y that i s usually  alleviated wi th addi tional, specific 
therapeuti c inter vention which is minimal, local or non -invasive. The event interferes 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 82of 116with usual  activi ties of  daily living, causing discomfort but poses no significant or 
perm anent ri sk of  harm  to the parti cipant.
Grade 3: A severe event that requires intensive therapeut ic intervent ion but is not 
immediately  life-threatening. The event interrupts usual act ivities o f daily living, or 
significant ly affects the clinical status of the participant. 
Grade 4: An event, and/or its immediate sequelae, that is associated with an i mminent ri sk 
of death and urgent intervention is indicated.
Grade 5: Death, as result of an event
It is important to dist inguish between serious and severe AEs. Severit y is a measure of 
intensity, whereas seri ousness is defined by  [CONTACT_244986] B2. An AE of severe 
intensity need not necessarily be considered serious. For example, nausea that persists for 
several hours may  be consi dered se vere nausea, but not a SAE unless it meets the criteria 
shown in Appendix B2. On the other hand, a stroke that results in only a limited degree of 
disabili ty may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Appendix B2.
B3 A Guide to Interpreting the Causality Question
When making an assessment of causalit y, consider the following factors when deciding if 
there is a ‘reasonable possibilit y’that an AE may have been caused by [CONTACT_33641].
Time Course. Exposure to suspect drug. Has the participant actually received the suspect 
drug? Did the AE occur in a reasonable temporal relat ionship to the administration of the 
suspect drug?
Consistency wit h known drug profile. Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
properties?
De-challenge experience. Did the AE resolve or improve on stoppi[INVESTIGATOR_122570]?
No al ternative cause. The AE cannot be reasonably explained by [CONTACT_670111], such as 
the underlying disease, other drugs, other host, or environmental factors.
Re-challenge experi ence. Di d the AE reoccur if the su spected drug was reintroduced after 
having been stopped? [COMPANY_008] would not normally reco mmend or support a 
re-challenge .
Laboratory  tests. A specific laboratory  invest igation (if performed) has confirmed the 
relationship .
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 83of 116In difficult cases, other fac tors coul d be considered, such as:
Is this a recogni zedfeature of overdose of the drug?
Is there a known mechanism?
Causalit y of ‘related ’ is made if, fo llowing a review of the relevant data, there is evidence for 
a ‘reasonable possibilit y’of a causal r elationship for the individual case. The expressio n 
‘reasonable possibilit y’ of acausal  relati onship is meant to convey , in general , that there are 
facts (evidence) or arguments to suggest a causal relat ionship.
The causalit y assessment i s perform ed based on the available data, including enough 
inform ation to m ake an informed judgment. W ith limited or no available facts or arguments to 
suggest a causal relat ionship, the event(s) will be assessed as ‘not rel ated’.
Causal relat ionship in cases where the DUS has deteriorated due to lack of effect should be 
classified as no reasonable possibilit y.
B4 Medication Error
For the purposes of this clinical study , a m edicat ion error is an unintended failure or mistake 
in the treatment process for an [COMPANY_008] IMP that either causes harm to the participant or 
has the potential to cause harm to the participant. 
A medicat ion error i s not l ack of  efficacy of the drug, but rather a human or process -related 
failure while the drug is in control of the study  site staf f or parti cipant.
Medicat ion error includes situat ions where an error: 
Occurred
Was i dentified and intercepted befo re the parti cipant received the drug
Did not occur, but circumstances were recognized that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name [CONTACT_33165] n
Dispensing error, eg, medicat ion prepared incorrectly, even if it was not actually given to 
the participant
Drug not administered as indicated, eg, wrong route or wrong site of administration
Drug not taken as indicated, eg, tablet disso lved in water when it should be taken as a 
solid tablet 
Drug not stored as instructed, eg, kept in the fridge when it should be at room temperature 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 84of 116Wrong participant received the medicat ion (excluding IRT/RTSM errors)
Wrong drug administered to participant (excluding IRT/RTSM errors)
Examples of events that do n otrequire reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IRT/RTSM -including those that led to one of the 
above listed events that would otherwise have been a medication error 
Parti cipant acci dentally  missed drug dose(s), eg, forgot to take medication
Accidental  overdose (will be captured as an overdose)
Parti cipant f ailed to return unused medicat ion or empt y packaging
Errors related to background and rescue medicat ion, or standard of care medicat ion in 
open -labelstudi es, even if an [COMPANY_008] product 
Medicat ion errors are not regarded as AEs, but AEs may occur as a consequence of the 
medicat ion error .
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 85of 116Appendix CHandling of Human Biological Samples
C1 Chain of Custody
A full chain of custody  is maintained for all samples t hroughout their lifecycle.
The invest igator at each center keeps full traceability of co llected bio logical sam ples f rom the 
participants while in storage at the center until shipment or disposal (where appropriate) and 
records relevant processing information related to the samples while at the site.
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment, and keeps record of receipt of arrival and 
onward shipment or disposal.
[COMPANY_008] or delegated representatives will keep oversight of the ent ire life -cycle through 
internal  procedures, m onitoring of study  sites, auditing or process checks, and contractual 
requi rements of external laboratory  provi ders
Samples re tained for further use will be stored in the [COMPANY_008] -assigned bi obanks or other 
sample archive facilit ies and will be tracked by  [CONTACT_271130] T eam for the 
remainder of the sample lifecycle.
If required, [COMPANY_008] will ensure that remai ning bi ological samples are returned to the site 
according to local regulations or at the end of the retention period, whichever is earlier .
C2 Withdrawal of Informed Consent for Donated Biological Samples 
[COMPANY_008] ensures that bio logical samples are retu rned to the source or destroyed at the end 
of a specified period, as described in the informed consent.
If a participant withdraws consent to the use of donated bio logical  samples, the sam ples will 
be disposed of/destroy ed/repatriated, and the action docum ented. If samples are already  
analyzed, [COMPANY_008] is not obliged to destroy  the resul ts of this research.
Following wi thdrawal  of consent for bio logical samples, further study  partici pation shoul d be 
considered in relat ion to the wi thdrawal  processes out lined in the informed consent.
The invest igator:
Ensures participant’s withdrawal of informed consent to the use of donated samples is 
highlighted immediately to [COMPANY_008] or delegate.
Ensures that relevant human bio logical samples from  that parti cipant, if stored at the 
study  site, are immediately  identified, disposed of as appropriate, and the action 
docum ented.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 86of 116Ensures that the participant and [COMPANY_008] are informed about the sample disposal.
[COMPANY_008] ensures the organizat ion(s) ho lding the sampl es is/are inform ed about the 
withdrawn consent immediately and that samples are disposed of or repatriated as appropriate, 
and the action is documented and the study  site is notified.
C3 International Airline Transportation Association 6.[ADDRESS_904846] SAMPLES
International Airline Transportation Associat ion (IA TA) 
(https://www .iata.org/whatwedo/cargo/dgr/Pages/download.aspx ) classifies infect ious 
substances into 3 categories: Category  A, Category B, or Exempt
Category A Infectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal disease in 
otherwi se healt hy humans or animals. 
Category A Pathogens are, eg, Ebola, Lassa fever virus. Infect ious substances meet ing these 
criteria which cause disease in humans or both in humans and animals must be assigned to 
UN2814. Infect ious substances which cause disease only in animals must be assigned to 
UN2900.
Category B Infectious Substances are infect ious substances that do not meet the criteria for 
inclusio n in Category  A. Category  B pathogens are, eg, Hepatitis A, C, D, and E viruses. They 
are assigned the fo llowing UN number and proper shippi[INVESTIGATOR_72919]:
UN 3373 –Biological Substan ce, Category  B
Are to be packed in accordance with UN [ADDRESS_904847] to these regulat ions, unless they 
meet the criteria for inclusio n in another class.
Clinical study  samples will fall into Category  B or exempt under IATA regulat ions
Clinical study  samples will routinely  be packed and transported at ambient temperature in 
IATA 650 compliant packaging 
(http s://www.iata.org/whatwedo/cargo/dgr/Documents/DGR -60-EN-PI650.pdf)
Biological samples transported in dry  ice requi re addi tional dangerous goods specificat ion 
for the dry -ice content
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 87of 116Appendix DActions Required in Cases of Increases in Liver Biochemistry 
and Evaluatio n of Hy’s Law
D1 Introduction
This Appendix describes the process to be fo llowed in order to i dentify and appropriately 
report PHL  cases and HL  cases. It is not intended to be a comprehensive guide to the 
management of elevated liver biochemistries. 
During the course of the study , the investigator will remain vigilant for increases in liver 
biochemistry . The investigator is responsible for determining whether a participant meets PHL  
criteria at any  point during the study .
All sources of l aboratory  data are a ppropri ate for the determinat ion of PHL  and HL  events; 
this includes samples taken at scheduled study  visits and other vi sits, including central  and all 
local laboratory  evaluat ions even if co llected outside of the study  visit s; eg, PHL  criteria coul d 
be met by  [CONTACT_670112] m a central  laboratory  and/or elevated TBL  from a local 
laboratory . 
The invest igator will also review AE data (eg, for AEs that may indicate elevat ions in liver 
biochemistry ) for possible PHL  events.
The invest igator participates, together with [COMPANY_008] clinical project representatives, in 
review and assessment of cases meet ing PHL  criteria to agree whether HL  criteria are m et. HL  
criteria are met if there is no alternat ive explanation for the elevat ions in liver biochemistry  
other than DILI caused by [CONTACT_2203] . 
The invest igator is responsible for recording data pertaining to PHL/HL  cases and for 
reporting SAEs and AEs according to the outcome of the review and assessment in line with 
standard safet y reporting processes.
D2 Definitio ns
Potential Hy’s Law
AST or ALT ≥3×ULN together  with TBL ≥2 ×ULN at any  point during the study  
following the start of study  medicat ionirrespect ive of an increase in ALP .
Hy’s Law
AST or ALT ≥3×ULN together  with TBL ≥2×ULN, where no other reason , other than the 
IMP, can be found to explain the co mbinat ion of increases, eg, elevated ALP indicat ing 
cholestasis, viral hepat itis, another drug. 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 88of 116For PHL  and HL, the elevat ion in transaminases must precede or be coincident with (ie, on the 
same day ) the elevati on in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL  must occur .
D3 Identification of Potential Hy’s Law Cases
In order to i dentify  cases of PHL, i t is important to perform a comprehensive review of 
labor atory  data for any  parti cipant who m eets any of the fo llowing identificat ion criteria in 
isolation or in combinat ion:
ALT ≥3×ULN
AST ≥3×ULN
TBL ≥2×ULN
If Central Laboratories are Being Used:
When a participant meets any of the PHL  identification criteria, in isol ation or in co mbinat ion, 
the central  laboratory  will immediately send an alert to the investigator (also sent to 
[COMPANY_008] representative). 
The invest igator will also remain vigilant for any local laboratory reports where the PHL  
ident ification criteria are met; where this is the case, the invest igator will:
Request a repeat of the test (new blood draw) by  [CONTACT_122647]
Com plete the appropri ate unscheduled laboratory  eCRF m odule(s) wi th the ori ginal  local 
laborator y test resul t
When the identificat ion criteria are m et from central  or local laboratory  resul ts, the 
investigator, will wit hout del ay:
Determine whether the participant meets PHL criteria (see Section D2for definit ion) by 
[CONTACT_33156] (incl uding both central  and l ocal 
laboratory  resul ts)
If Local Laboratories are Being Used:
The invest igator, will without del ay, review each new l aboratory  report and if the 
ident ificat ion criteria are met will:
Determine whether the participant meets PHL criteria (see Section D2for definit ion) by 
[CONTACT_33156]
Prom ptly enter the laboratory  data into the l aboratory  eCRF
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 89of 116D4 Follow -up
D4.1 Potential Hy’s Law Criteria not met
If the participant does not meet PHL  criteria the investiga tor will:
Inform  the [COMPANY_008] representative that the participant has not met PHL criteria.
Perform  follow-up on subsequent laboratory  resul ts according to the guidance provided in 
the CSP.
D4.2 Potential Hy’s Law Criteria met
If the participant does meet PHL criteria the investigator will:
Notify  the [COMPANY_008] representative who will then inform the central Study  Team  
Within one day  of PHL cri teria being m et, the investi gator will report the case as an SAE 
of PHL; seri ous cri teria ‘Im portant m edical  event’ and causalit y assessment ‘y es/related’ 
according to CSP process for SAE reporting.
For parti cipants that met PHL criteria prior to starting IMP, the invest igator is not 
requi red to submit a PHL SAE unless there is a significant change#in the participa nt’s 
condi tion
The Study  Physician contacts the investigator, to provide guidance, discuss and agree an 
approach for the study  parti cipants’ fo llow-up (including any further laboratory  testing) 
and the continuous review of data
Subsequent to this contact [CONTACT_33157]:
Moni tor the parti cipant until liver bio chemistry  param eters and appropri ate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically indicated. 
Com pletes foll ow-up SAE Form as required.
Invest igate the etiology of the event and perform diagnostic investigat ions as discussed 
with the Study  Physician. 
Com plete the 3 Liver eCRF Modules as informat ion beco mes available 
#A ‘significant ’ change in the participant ’s condi tion refers to a clinically  relevant change 
in any of the individual liver biochemistry  parameters (AL T, AST or TBL) in iso lation or i n 
combinat ion, or a clinically  relevant change in associated symptoms. The determination of 
whether there has been a significant change will be at the discret ion of the investigator, this 
may be in consultat ion with the Study  Physician if there is any uncertaint y.
D5 Review and Assessment of Potential Hy’s Law Cases
The instructions in this Section should be fo llowed for all cases where PHL  criteria are m et.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 90of 116As so on as possible after the biochemistry  abnormalit y was ini tially detected, the Study  
Physician contacts the invest igator in order to review available data and agree on whether 
there is an alternat ive explanat ion for meeting PHL  criteria other than DILI caus ed by  [CONTACT_86184], to ensure timely analysis and reporting to healt h authorit ies wit hin [ADDRESS_904848] and TBL  elevat ions, a 
determinat ion of whether the alternat ive explanat ion is an AE will be made and subsequent ly 
whether the AE meets the criteria for a SAE:
If the alternat ive explanat ion is notan AE, record the alternative explanati on on the 
appropriate eCRF
If the alternat ive explanat ion is an AE/SAE: update the previously submitted PHL SAE 
and AE eCRFs accordingly wit h the new informat ion (reassessing event term; causalit y 
and seriousness criteria) fo llowing the [COMPANY_008] standar d processes.
If it is agreed that there is no explanat ion that would explain the AL T or AST and TBL  
elevations other than the IMP:
Send updated SAE (report term ‘Hy’s Law’) according to [COMPANY_008] standard 
processes. 
The ‘Medically  Important’ seri ous cr iterion shoul d be used if no other serious criteria 
apply
As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If, there i s an unavo idable delay , of over 15 cal endar day s in obtaining the informat ion 
necessary  to assess whether or not the case meets the criteria for HL, then it is assumed that 
there is no alternat ive explanation unt il such time as an informed decisio n can be made:
Provi des any  further update to the previously submitted SAE of PHL, (report term now 
‘Hy’s Law case’) ensuring causalit y assessment i s related to IMP and seriousness criteria 
is medically important, according to CSP process for SAE reporting.
Continue fo llow-up and review according to agreed plan. Once the necessary  
supple mentary  informat ion is obtained, repeat the review and assessment to determine 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 91of 116whether HL criteria are still met. Update the previously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review and 
amending th e reported term if an alternat ive explanat ion for the liver biochemistry  
elevations is determined.
D6 Laboratory Tests
The list below represents the standard, comprehensive list of fo llow-up tests which are 
recommended but not mandatory  when using a central laboratory . For studi es using a l ocal 
laboratory , the list m ay be m odified based on clinical judgement. Any test results need to be 
recorded.
Hy’s Law Lab Kit for Central Laboratories 
Additional standard chemistry and coagulation 
testsGGT ( Gamma glutamyl transpeptidase)
LDH
Prothrombin time
INR
Viral hepatitis IgM ( immunoglobulin M ) anti -HAV
HBsAg
IgM and IgG ( immunoglobulin G) anti-HBc
HBV DNAa
IgG anti -HCV
HCV RNA b
IgM anti -HEV
HEV RNA
Other viral infections IgM & IgG anti -CMV
IgM & IgG anti -HSV
IgM & IgG anti -EBV
Alcoholic hepatitis Carbohydrate deficient transferrin 
(CD-transferrin) c
Autoimmune hepatitis Antinuclear antibody (ANA)
Anti-Liver/Kidney Microsomal antibody (Anti -
LKM)
Anti-Smooth Muscle antibody (ASMA)
Metabolic diseases alpha -1-antitrypsin
Ceruloplasmin
Iron
Ferritin
Transferrin
Transferrin saturation
aHBV DNA is only recommended when IgG anti -HBc is positive
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 92of 116bHCV RNA is only recommended when IgG anti -HCV is positive or inconclusive cCD-transferrin and Transferrin are not available in China. Study teams should amend this list accordingly
D7 References
Aithal et al, 2011
Aithal et al 2011, Clinical Pharmaco logy and Therapeutics 89(6):806 -815.
FDA Guidance for Industry, July 2009
FDA  Guidance for Industry  (issued July 2009) ‘Drug -induced liver injury: Premarket ing 
clinical evaluat ion’. Available fro m; https://www .fda.gov/regulatory -informat ion/search -fda-
guidance -docum ents/drug -induced -liver-injury -premarket ing-clinical -evaluati on
Clinical Stud y Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 93of 116Appendix EAnaphylaxis
In adults, anaphylaxis is highly likely  when any 1 of the following 3 criteria is fulfilled:
1Acute onset of an illness (minutes to several hours) with invo lvement of the skin, mucosal 
tissue, or both (eg, generalised hives, pruritus or flushing, swollen lips, tongue and/or 
uvula)
AND A T LEAST ONE OF THE FOLLOWING:
Respi[INVESTIGATOR_33097] (eg, dyspnoea, wheeze -bronchospasm, stridor, reduced peak 
expi[INVESTIGATOR_11311], hypoxaemia)
Reduced BP (see number 3 below for definit ion) or associated symptoms of end -
organ dysfunction (eg, hypotonia [collapse ], syncope, incont inence)
2Two or more of the fo llowing that occur rapi[INVESTIGATOR_11312] a likely allergen for that 
participant (minutes to several hours):
Involvement of the skin -mucosal t issue (eg, generalised hives, itch, flush, swo llen 
lips, tongue and/or uvula)
Respi[INVESTIGATOR_33097] (eg, dyspnoea, wheeze -bronchospasm, stridor, reduced peak 
expi[INVESTIGATOR_11311], hypoxaemia)
Reduced BP (see number 3 below for definit ion) or associated symptoms (eg, 
hypotoni a [collapse], syncope, incont inence)
Persi stent g astrointestinal symptoms (eg, crampy abdo minal pain, vo miting)
3Reduced BP after exposure to known allergen for that participant (minutes to several 
hours); for adults a sy stolic BP of less than 90 mm Hg or greater than 30% decrease from 
that person’s basel ine BP (taken at or immediately prior to start of the IMP 
administration), whichever BP is lower.
The fo llowing definit ions are provided for the purposes of this study :
Hypersensitivity r eaction: An acute onset of an illness with invo lvement of the skin, m ucosal  
tissue, or both after injection of IMP (but does not meet the definit ion of anaphylaxis 
described above).
To assist with the mit igation of these AEs, see Table12, whi ch categorizes react ions by 
[CONTACT_11370] y of symptom s and, proposes severit y-specific treatment and offers guidance on 
management of IMP . Final treatment is at the discretion of the investigator and should reflect 
local SOC.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 94of 116Table12 An Appr oach to Management of Anaphylactic, Hypersensitivity , and Post -injection Reactions
Severity of symptoms Treatment Investigational product
Mild local reactions (During and post injection 
and hypersensitivity)
Mild injection site reactions such as redness, mild 
swelling, pain at the injection site or headache, 
nausea, non -pruritic rash, or mild hypersensitivity 
reactions including localised at the injection site or 
generalized cutaneous reactions such as mild 
pruritu s, flushing, rash, dizziness, headache, ≤ 20 
mmHg change in systolic BP from 
pre-administration measurement.Evaluate participant, including close monitoring 
of vital signs.
At the discretion of the Investigator, treat 
participant, for example, with:
Localized cold pack or heat to the injection site. 
If more generalized reaction: 
• Diphenhy dramine 50 mg PO or equivalent 
and/o r
• Acetaminophen 500 to 650 mg or 
equivalent dose of paracetamol and/or
• Topi[INVESTIGATOR_189327]/or low -potency  
topi[INVESTIGATOR_670054]/or
• Anti-nausea medication, as needed.Pause or hold additional IMP injection 
immediately.
At the discretion of the Investigator, resume 
current IMP administration under observation. 
Moderate reactions (during or immediately post 
injection)
Injection site reaction such as those listed above 
under mild reactions but excluding moderate 
hypersensitivity reactions (see below).Evaluate participant, including close monitoring 
of vital signs.
Treat participant, for example, with:
• Normal saline (~500 to 1000 mL/hour IV)
• and/o r
• Diphenhy dramine 50 mg IV or equivalent 
and/o r
• Acetaminophen 500 to 650 mg or 
equivalent dose of paracetamol and/or
• Anti-nausea and/or antiemetic 
intramuscular, as needed.Stop or hold additional IMP administration 
immediately.
At the discretion of the Investigator, resume 
current IMP administration under observation. 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 95of 116Table12 An Appr oach to Management of Anaphylactic, Hypersensitivity , and Post -injection Reactions
Severity of symptoms Treatment Investigational product
Moderate hypersensitivity reactions
Reactions which may include generalised rash or 
urticaria, palpi[INVESTIGATOR_814], chest discomfort, shortness 
of breath, h ypo-or hypertension with
> 20 mmHg change in systolic BP
from pre -infusion measurement.Evaluate participant, including close monitoring 
of vital signs.
Treat participant, for example, with:
• Normal saline (~500 to 1000 mL/hour IV)
• and/o r
• Diphenhy dramine 50 mg IV or equivalent 
and/o r
• Acetaminophen 500 to 650 mg or 
equivalent dose of paracetamol and/or
• IV corticosteroids, such as hydrocortisone 
100 mg o r methy lprednisolone 20 to 40 
mg.Stop IMP administration immediately. 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 96of 116Table12 An Appr oach to Management of Anaphylactic, Hypersensitivity , and Post -injection Reactions
Severity of symptoms Treatment Investigational product
Severe
Above plus fever with rig ors, hypo -or hyperte nsion 
with ≥40 mmHg change in systolic BP, signs of
end-organ dysfunction (eg, symptomatic 
hypotension such as hypotonia, syncope, 
incontinence, seizure) from pre -infusion 
measurement, or wheezing, angioedema, or stridor
OR
Life-threat ening
Defined as a reaction that is
life-threatening and requires pressor and/or 
ventilator support or shock
associated with acidemia and
impairing vital organ function due to tissue 
hypoperfusionEvaluate participant, including close monitoring 
of vital signs.
Maintain airway, oxygen if available.
Treat participant immediately, for example 
with:
• Normal saline (~500 to 1000 mL/hour IV)
• Epi[INVESTIGATOR_179521], 
hypotension unresponsive to IV fluids, or 
angioedema. Dose and route as per local 
SOC, example, epi[INVESTIGATOR_238] 1:1000, 0.5 to 
1.0 mL administered SC for mild cases and 
intramuscular for more severe cases
• IV corticosteroids, such as hydrocortisone
• 100 mg o r methy lprednisolone 20 to 40 
mg
• Diphenhy dramine 50 mg IV or equivalent
• Acetaminophen 500 t o 650 mg or 
equivalent dose of paracetamol
Call emergency medical transport for transport 
to emergency hospi[INVESTIGATOR_670055].
Grade 3 wheezing, hypotension or angioedema 
is unresponsive to single dose of epi[INVESTIGATOR_670056] 4 event
At the discretion of the investigatorStop IMP administration immediately. Do not 
resume current dosing. Permanently 
discontinue IMP administration.
Consider need for additional oral 
antihistamine administration or oral 
corticosteroid administration to prev ent 
reoccurrence of symptoms over subsequent 2 
to 3 days.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 97of 116Appendix Fe-Diary
Symptoms Associated with Covid -[ADDRESS_904849] one 
(ie, ____ °F/°C).
(a)Free text input
Move to Question [ADDRESS_904850] you experienced shortness of breath?
(a)No
(b)Yes
If No, move to Question 4
If Yes, move to Question 3
3Grade the severit y of shortness of breath based on the descript ions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with activity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904851] you experienced difficult y breathing?
(a)No
(b)Yes
If No, move to Question 6
If Yes, move to Question 5
5Grade the severit y of the difficult y breathing based on the descript ions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670058] –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 98of 116Move to Question [ADDRESS_904852] you experienced chills?
(a)No
(b)Yes
If No, move to Question 8
If Yes, move to Question 7
7Grade the severit y of chills based on the descriptions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904853] you experienced a cough?
(a)No
(b)Yes
If No, move to Question 10
If Yes, move to Question 9
9Grade the severit y of cough based on the de scriptions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904854] you experienced fat igue?
(a)No
(b)Yes
If No, move to Question 12
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 99of 116If Yes, move to Question 1 1
11Grade the severit y of fatigue based on the descript ions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily activity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904855] you experienced muscle aches?
(a)No
(b)Yes
If No, move to Question 14
If Yes, move to Question 13
13Grade the severit y of muscle aches based on the descript ions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904856] you experienced body  aches?
(a)No
(b)Yes
If No, move to Question 16
If Yes, move to Question 15
15Grade the severit y of body  aches based on the descriptions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670058] –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 100of 116Move to Question [ADDRESS_904857] you experienced headache?
(a)No
(b)Yes
If No, move to Question 18
If Yes, move to Question 17
17Grade the severit y of headache based on the descriptions below:
(a)1 (Mild): No interference wit h act ivity
(b)2 (Moderate): Repeated use of non -narcoti c pain reliever
(c)3 (Severe): Significant, any  use of narcotic pain reliever or prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904858] you experienced new lo ss of taste?
(a)No
(b)Yes
If No, move to Question 20
If Yes, move to Question 19
19Grade the severit y of loss of taste based on the descript ions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904859] you experienced new loss of smell?
(a)No
(b)Yes
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 101of 116If No, move to Question 22
If Yes, move to Question 21
21Grade the severit y of loss of smell based on the descript ions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904860] you experienced a sor e throat?
(a)No
(b)Yes
If No, move to Question 24
If Yes, move to Question 23
23Grade the severit y of sore throat based on the descriptions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904861] ion?
(a)No
(b)Yes
If No, move to Question [ADDRESS_904862] ion based on the descriptions be low:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 102of 116(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904863] you experienced a runny  nose?
(a)No
(b)Yes
If No, move to Question 28
If Yes, move to Question 27
27Grade the severit y of runny  nose based on the descri ptions bel ow:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily activity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904864] you experienced nausea?
(a)No
(b)Yes
If No, move to Question 30
If Yes, move to Question 29
29Grade the severit y of nausea based on the descript ions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_670057] [ADDRESS_904865] you experienced vo miting?
(a)No
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 103of 116(b)Yes
If No, move to Question 32
If Yes, move to Question 31
31Grade the severit y of vomiting based on the descriptions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER vi sit or hospi [INVESTIGATOR_670057] [ADDRESS_904866] you experienced diarrhea?
(a)No
(b)Yes
If No, e -Diary can be submitted.
If Yes, move to Question 33
33Grade the severit y of diarrhea based on the descriptions below:
(a)1 (Mild): No interference with act ivity
(b)2 (Moderate): Some interference with act ivity
(c)3 (Severe): Significant, prevents daily act ivity
(d)4 (ER or hospi[INVESTIGATOR_21186]): ER visit or hospi[INVESTIGATOR_3094]
e-Diary can be submitted
For Patients ≥60 years of age ONL Y: 
1Have you felt as if y ou can’t think clearly?
(a)No
(b)Yes
2Have you experienced any  loss or decrease in y our appeti te?
(a)No
(b)Yes
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 104of 1163Do y ou take supplemental oxygen?
(a)No
(b)Yes
If No, e -Diary can be submitted.
If Yes, move to Question [ADDRESS_904867] you needed to increase y our baseline intake?
(a)No
(b)Yes
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 105of 116Appendix GECOG Performance Status
GRADE ECOG PERFORMANCE STATUS
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, eg, light house work, office work
2 Ambulatory and capable of all selfcare but unable to carry out any work 
activities; up and about more than 50% of waking hours
3 Capable of only limited selfcare; confined to bed or chair more than 50% of 
waking hours
4 Completely disabled; cannot carry on any selfcare; totally confined to bed or 
chair
5 Dead
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 106of 116Appendix HAbbreviations
Abbreviation or 
special term Explanation
ADA anti-drug antibody 
AE adverse event
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase/transaminase
AST aspartate aminotransferase/transaminase
AUC area under the plasma concentration -time curve
β-hCG beta-human chorionic gonadotropin
BSSR blinded sample size re -estimation
CI confidence interval
CONSORT Consolidated Standards of Reporting Trials
COVID -[ADDRESS_904868]
DUS Disease Under Study
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic Case Report Form
ELF epi[INVESTIGATOR_670059]γR Fc gamma receptor(s)
FcRn neonatal Fc receptor(s)
FTIH first time in human
FSH follicle stimulating hormone
GCP Good Clinical Practice
HIV human immunodeficiency virus
Clinical Study Protocol –6.0 [COMPANY_008]
AZD74 42–D8850C00003
CONFIDENTIAL AND PROPRIETARY 107of 116Abbreviation or 
special term Explanation
HL Hy’s Law
IB Investigator’s Brochure
IATA International Airline Transportation Association
IC80 80% maximal inhibitory concentration
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IgG immunoglobulin G
IgM immunoglobulin M
IM Intramuscular
IMP Investigational Medicinal Product
IRB Institutio nal Review Board
IRT Interactive Response Technology
IV Intravenous
LTCF long-term care facilities
MAAE medically attended adverse event
mAbs monoclonal antibodies
MERS Middle East respi[INVESTIGATOR_670060] -CoV Middle East respi[INVESTIGATOR_670061]-observed -adverse -effect level
NP Nasophary ngeal
PHL Potential Hy’s Law
PI [INVESTIGATOR_670062](s)
RBD receptor binding domain
RNA ribonucleic acid
RRR relative risk reduction
RT-PCR reverse transcriptase polymerase chain reaction
RTSM Randomization and Trial Supply Management
S Spi[INVESTIGATOR_670063] -CoV -2 severe acute respi[INVESTIGATOR_7686] -coronavirus 2
sgmRNA subgenomic RNA
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 108of 116Abbreviation or 
special term Explanation
SoA Schedule of Activities
t1/[ADDRESS_904869] upper limit of normal
WOCBP women of childbearing potential
YTE Immunoglobulin constant heavy chain substitution to modify the half -life of the 
antibody (M252Y/S254T/T256E)
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 109of 116Appendix IProtocol Amendment History
The Protocol Amendment Summary  of Changes T able for the current amendment is located 
directly before the T able of Contents.
Version 5.0, 21 December  2020
Key amendment and rationale for  change:
After cl arificati on in Amendment 3, on the use of SARS -CoV-2 vaccines in study  
participants, further clarificat ion was required to ensure participant safety  and stati stical 
accountabilit y for those unblinded part icipants considering vaccinat ion for COVID -19. 
Synopsis, Sections 3 (Objectives and Endpoints), 9.4.1 (General Considerations): To 
account for increased availabilit y of COVID -19, vaccines the definit ion of intercurrent 
events was expanded to include “beco me unblinded to properly consider vaccinat ion for 
COVID -19”.
Table 1 (Schedule of Activities: T reatment and Follow -up Period –Main Study) : 
Instructi ons added to footnote ‘a’ to define how exposure to COVID -19 should be 
confirmed. 
Section 6.5.1 (COVID -19 Vaccine) : Changes made to the procedures req uired to allow 
potenti al and current study  parti cipants to receive a COVID -19 vaccine.
Section [IP_ADDRESS] (Primary Endpoint) : Text added to clarify a final analysis will be 
conducted at end of study .
Version 4.0, 16 December  2020
Key amendments and rationale for  change:
Highly efficacious vaccines against SARS -CoV-2 are being deplo yed on a mass scale. T op 
priority target populat ions for vaccine administration in both the [LOCATION_006] and US include 
residents of L TCF. These L TCF resi dents are a key target popul ation for this study , with up 
to 80% of the study  popul ation to be drawn from them. Given the extreme vulnerabilit y of 
this popul ation, and the apparent ly high efficacy o f the vaccines in the elderly , our study  
shoul d not del ay or obstruct vaccine access t o those who could benefit from it. Therefore, 
guidance for SARS -CoV-[ADDRESS_904870] changing expectations regarding 
the attack rate and assumed efficacy . These changes are based on external informat ion 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 110of 116concerning possible treatments, prevent ion of COVID -[ADDRESS_904871] from participat ion in this study . 
After rando mizat ion, they  are permi tted at any  point during the study  other than the day  of 
IMP administration.
Allowing the use of other mAbs during the study  does not appear to pose an y safet y risk. 
AZD7442's mAbs bind specifically to the receptor binding domain of the Spi[INVESTIGATOR_144870] o f 
SAR -CoV-2, but not to human targets. Published mAb -mAb interact ion studi es are rare. 
One clinical study  of coadministration of pertuzumab and trastuzumab + docetaxel via 
separate infusio ns, which each bind to different epi[INVESTIGATOR_665040]2 receptor, illustrated 
that the PK of one mAb is not affected by [CONTACT_670113] (Cortés et al 
2013 ). Therefore, it is not expected that the action of AZD7442 will be affected by  [CONTACT_670114], including its PK parameters, clearance and eliminat ion. Any 
potenti al impact on AZD7442 PK will be examined for any  parti cipants that have received a 
commercial mAb.
Due to the ongoing unprecedented situation caused by  [CONTACT_25963] -[ADDRESS_904872] oyees has been 
amended to allow those emplo yees and their family members not involved in AZD7442 
development to receive the IMP if eligible for the study .This change aligns this restriction 
with the exclusio n criterion currently used in [COMPANY_008] ’s clin ical study  of its 
anti-SARS-CoV-[ADDRESS_904873] ing precedent.
Synopsis, Figur e 1 (Study Design), Sections 4.1 (Overall Design), 9.1 (Statistical 
Hypotheses), 9.2 (Sample Size Determination), [IP_ADDRESS] (Primary Endpoint), 9.5
(Interim Analyses), and Appendix A5 (Committees Structur e): Text changed to include 
an interim analysis after [ADDRESS_904874] ing changing expectations regarding the attack rate and 
assumed efficacy rate, based on external information. 
Synopsis, Sections 4.1 (Overall Design) and 6.3.1 (Randomization): The proportion of 
total parti cipant recruit ment not to be exceeded in Cohort 2 was changed from 50% to 80%.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 111of 116Table 1 (Schedule of Activities: T reatment and Follow -up Period –Main Study): For 
clarity ‘early ’ has been added to the discontinuat ion visit column header .
Table 1 (Schedule of Activ ities: T reatment and Follow -up Period –Main Study), T able 
2 (Schedule of Activities: Illness V isits), and Section [IP_ADDRESS] (Assessment of Mucosal 
Responses): To allow for logist ical problems caused by  [CONTACT_25963] -[ADDRESS_904875] supplies are 
not available. 
Section 2.3.1 (Risk Assessment): The date of the data cut -off for risk assessment has been 
changed to [ADDRESS_904876] the ongoing Study  D8850C00001.
Section 5.2 (Exclusion criteria): Criterion 8 ‘Recei pt of blood products or 
immunogl obulins, including mAbs, within 6 months, or 5 antibody  half-lives if lo nger than 
6 months, pri or to screening (see T able 6)’ has been deleted per the rationale provided 
above.
Section 5.2 (Exclusion Criteria): Criterion changed fro m: ‘12. Employees of the Sponsor, 
clinical study  site, or any  other individuals invo lved with the conduct of the study , or 
immediate family members of such individuals ’ to ‘11. Employees of the Sponsor i nvolved 
planning, executing, supervising, or reviewing the AZD7442 program, clinical study  site 
staff, or any other individuals invo lved with the conduct of the study , or immediate family  
members of such individuals ’.
Table 6 (Permitted, Restricted, and Pr ohibited Medications): The instruction that any  
SARS -CoV-2 or COVID -19 vaccines should not be considered a routine vaccine, has been 
added. 
New Section 6.5.1 (COVID -19 Vaccine): New section added to describe the procedures 
requi red to all ow potenti al and current study  parti cipants to receive a COVID -19 vaccine.
Section 8.1.2 (Sever e or Critical Criteria): Severe COVID -19 definit ion updated to match 
all AZD7442 studies ‘either pneumo nia (fever, cough, tachypnea, dyspnea, lung infiltrates) ’ 
changed to ‘eitherpneum onia (fever, cough, tachypnea, ordyspnea, and lung infiltrates) ’.
Section 8.1.3 (Illness V isits): Text added to confirm that qualified staff should conduct 
home visits. 
Section 8.2.4 (Clinical Safety Laboratory Assessments): For cl arity regarding r equired 
laboratory  tests the cal culat ion of eGFR has been added.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 112of 116Section 9.4 (Statistical Analyses): Added cl arificati on that Sponsor/designated clinical 
research organizat ion associ ated wi th the analysis, wri te-up and submissio n will be 
unblinded if overwhelming efficacy  is dem onstrated during interim analysis.
Sections 9.4 (Statistical Analysis) and 9.5 (Interim Analyses): Changes to the text to 
reflect that the planned DSMB assessments will now include a separate unblinded analysis 
team , designated by [CONTACT_1034], for the early efficacy and safet y assessments. 
Corrected ty pos have not been listed above. 
Version 3.0, 13 November  2020
Key amendment and rationale for  change:
Changes have been made to the protocol in response to health authorit y comments, which 
requested the inclusio n of increased safet y monitoring wi th particular em phasis on potenti al 
hypersensit ivity react ions immediately  after IMP  administrati on. As o f [ADDRESS_904877] acebo.
Title Page: Updated to include study acronym.
Synopsis, Figure 1 (Study  Design), Secti ons 4.1 (Overall Design), 9.4 (Statist ical Analyses), 
[IP_ADDRESS] (Primary  Endpoint), and 9.5 (Interim Analyses): Sections updated to include an 
interim analysis after 50% of the total statist ical information is available, approximately 45 
events.
Synopsis, T able 1 (Schedule of Activities: T reatment and Follow -up Period –Main 
Study), Section 4.1 (Overall Design), and New Section Added [IP_ADDRESS] (Monitoring After  
IMP  Administration): To increase safet y monitoring immediately after IMP administration 
a Sentinel Cohort has been included, so that the first [ADDRESS_904878] IMP 
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 113of 116administration. In addit ion, the Sentinel Cohort will be contact[CONTACT_632499] 4 day s 
after IMP  administration. 
Synopsis, Section 9.2 (Sample Size Determination): Further details add ed on the sam ple 
size assumpt ions.
Synopsis, Section 9.6 (Data Safety Monitoring Board), and Appendix A5 (Committees 
Structure): Text added to clarify the frequency o f the data review meet ing, and confirm 
that there is only  one f ormal efficacy  look by  [CONTACT_670115][INVESTIGATOR_670064] (ie, the interim analysis). Added cri teria for pausing 
the study  for DSMB revi ew to ensure safet y oversight (ie, halt ing the tri al if AZD7442 is 
harmful).
Table 1 (Schedule of Activities: T reatment and Follow -up Period –Main Study): The 
time frame for the index SARS -CoV-[ADDRESS_904879] 
15 participants (Sent inel Cohort) will be contact[CONTACT_670116] y monitoring during the 
first 4 day s after IMP administration.
Table 1 (Schedule of Activities: T reatment and Follow -up Period –Main Study) and 
Section 8.2.5 (Injection Site Inspection) : Instructio ns adde d to f ootnote to i ncrease the 
number of times the inject ion site is inspected after IMP administration and in the main 
body  a list of assessments to be performed described.
Table 1 (Schedule of Activities: T reatment and Follow -up Period –Main Study) and 
Section 5.1 (Inclusion Criteria): Addit ion of inclusion criterion and modificat ion to 
schedule of events clarifying that a negative SARS -CoV-[ADDRESS_904880] resul t is requi red at 
screening for inclusio n in the study . 
Table 2 (Schedule of Activities: Illnes s Visits): An addit ional self-collected nasal swab for 
viral shedding omitted fro m the original protocol  added to IL -D11.
Table 2 (Schedule of Activities: Illness V isits), Sections 8.1.1 (Monitoring COVID -19 
Symptoms), and 8.1.3 (Illness V isits): Table headers updated for clarit y. Footn otes added 
to clarify  the use of l ocal versus central  laboratory  resul ts, to all ow home visi ts if necessary , 
and to specify that the Illness V isit schedule should be completed in addit ion to the Main 
Study  schedule. 
Section 5.2 (Exclusion Criteria): Addit ion of new criterion to exclude participants who 
lack capacit y to provi de thei r own inform ed consent in jurisdictions where this is not 
permitted.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 114of 116Section 6.1.1 (IMP): Text added to clarify that should a participant experien ce an 
immediate hy persensi tivity reacti on after recei pt of the first IM inject ion, the second IM 
inject ion shoul d not be given. Instructions for anaphylact ic react ions added to Appendix E.
Section 6.3.1 (Randomization): A reference to stratificat ion was in correctly  included in the 
original  protocol , text updated to ‘rando mizat ion will be maintained in a 2:1 ratio within 
each of the 2 cohorts ’.
Table 6 (Permitted, Restricted, and Pr ohibited Medications): Updated to specify that 
participants who develop COVID -[ADDRESS_904881] of care, including investigational agents outside a clinical trial setting. 
Section 7.4 (Study Suspension/Early T ermination): Secti on updated to include stoppi[INVESTIGATOR_670065] a grade IV or SAE hypersensit ivity react ion occur . 
Furtherm ore, the study  will be paused should a grade III hy persensi tivity or a grade III 
inject ion site reaction(s) occur within the first 100 participants. Due to the age and 
comorbidi ty profile of the study  popul ation, the grade III hy persensi tivity/injecti on si te 
reacti on stoppi[INVESTIGATOR_670066] 100 participants, this is to reduce the 
likelihood of unrelated events temporarily stoppi[INVESTIGATOR_10098] .
Section 8.1.2 (Sever e or Critical Criteria): Modified to correctly correspond with severe 
or cri tical criteria for COVID -19 based on pneumo nia or hy poxemia parameters and the 
WHO clinical progression scale. WHO clinical progressio n scale updated to the recently 
published 10 -point g uideline.
Sections 8.1.1 (Monitoring COVID -19 Symptoms) and 8.3.6 (Adverse Events Based on 
Signs and Symptoms): Clarified that symptoms of COVID -19, confirmed SARS -CoV-[ADDRESS_904882] ion, and/or diagnosis of COVID -19 will be collected and recorded in the eCRF as an 
AE.
Section 8.1.6 (Illness e -Diary) and New Appendix F  (e-Diary): To allow for version 
control  the e -Diary has been added to the appendices. 
Section [IP_ADDRESS] (Females Only): Footnotes added to clarify pregnancy and FSH testing. 
Section 8.3.2 (Follow -upof AEs and SAEs ) and Appendix B2 (Definition of Serious 
Adverse Events): Severit y ratings adj usted to align wi th CTCAE event grading.
Section 8.3.4 (Adverse Events of Special Inter est) and New Appendix Added Appendix 
E (Anaphylaxis): Appendix E added to d escribe definit ion and management of anaphylaxis 
and other hy persensi tivity/administration reactions. Inject ion site reaction(s) added as an 
AESI.
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 115of 116Synopsis, Sections 9.1 (Statistical Hypotheses), 9.2 (Sample Size Determination), 
[IP_ADDRESS] (Primary Endpoint), and [IP_ADDRESS] (Secondary Analysis): Removal of “lower bound 
of 2-sided 95% CI is required to be greater than 30%” constraint from the statist ical 
significance cri teria. The null hypothesis testing no difference between AZD7442 and 
placebo groups i s consider ed sufficient for demonstrating statist ical superi ority over 
placebo in a m ore targeted populat ion. 
Section 9.4.5 (Methods for  Multiplicity Contr ol):To reflect changes in CI the methods 
for multiplicity control  were updated. 
Version 2.0, 26 October  2020
Key amendment and rationale for  change:
Synopsis, and Section 7.4 (Study Suspension/Early T ermination): Addit ion of wording 
that if the study  is suspended and does not proceed fo llowing evaluat ion of cumulat ive 
safet y data fro m the first [ADDRESS_904883] parti cipant 
dosed, a protocol amendment will be submitted to Healt h Aut horities.
Version 1.0, 07 October  2020
Initial creat ion
Clinical Study Protocol –6.0 [COMPANY_008]
AZD7442 –D8850C00003
CONFIDENTIAL AND PROPRIETARY 116of [ZIP_CODE] REFERENCES
CDC. (Centers for Disease Control and Prevent ion). Coronavirus Disease 2019 (COVID -19), 
Symptom s of Coronavrus. https://www .cdc.gov/coronavirus/2019 -ncov/symptom s-
testing/symptoms.ht ml. Published 2020. Accessed 01 July 2020.
Cortés J, Swain SM, Kudaba I, Hauschild M, Patel T , Grincuka E et al. Absence of 
pharmacokinet ic drug -drug interaction of pertuzumab with tras tuzum ab and docetaxel . 
Anticancer Drugs. 2013;24(10):1084 -92.
Gorbal enya A, Baker S, Baric R, de Groot R, Drosten C, Gulyaeva A  et al . The species Severe 
acute respi[INVESTIGATOR_82326] e-related coronavirus: classifying 2019 -nCoV and naming it SARS -
CoV-2. Natur e microbio logy. 2020;5(4):[ADDRESS_904884] ion, and Evo lution of Coronavirus Spi[INVESTIGATOR_103184]. Annu Rev Viro l. 
2016;3(1):237 -61.
Marshall JC, Murthy  S, Di az J, Adhikari NK, Angus DC, Arabi YM et al. A minima l commo n 
outcom e measure set for COV ID-19 clinical research. The Lancet Infectious Diseases. 
2020;20(8):e192 -e7.
Miettinen O, Nurminen M. Comparat ive analysis of two rates. Stat Med. 1985;4(2):213 -26.
NIH. (Nati onal Institutes of Health). Commo n Termino logy Criteria f or Adverse Events 
(CTC AE) V ersion 5.0. 
https://ctep.cancer .gov/protocolDevelopment/electronic_applicat ions/ctc.ht m#ctc_50. 
Published 2017. Accessed 11 November 2020.
WHO. WHO Coronavirus Disease (COVID -19) Dashboard.  2020.
Xie Y, Wang Z, Liao H, Marley  G, W u D, T ang W . Epi [INVESTIGATOR_50123], clinical, and laboratory  
findings of the COVID -19 in the current pandemic: sy stem atic review and meta -analysis. 
BMC Infect Dis. 2020;20(1):640.
Zhou P , Yang X -L, W ang X -G, Hu B, Zhang L, Zhang W  et al . A pneumo nia outbreak 
associ ated wi th a new coronavi rus of  probable bat ori gin. Nature. 2020;579(7798):270 -3.
Zou G. A modified poisson regressio n approach to prospective studies with binary  data. Am J 
Epi[INVESTIGATOR_176310]. 2004;159(7):[ADDRESS_904885] that was signed
electronically and this page is the manifestation of the electronic signature
[CONTACT_24558]: d8850c00003-csp-v6
Document Title: D8850C00003 Clinical Study Protocol version 6
Document ID: Doc ID-004386312
Version Label: 6.[ADDRESS_904886] APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by [CONTACT_24557]
12-Mar-2021 20:30 UTC Content Approval
12-Mar-2021 18:07 UTC Management Approval
12-Mar-2021 21:48 UTC Content Approval
12-Mar-2021 16:32 UTC Content Approval
Notes: (1) Document details as stored in ANGEL, an [COMPANY_008] document management system.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]